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resumo 
 
 
A procura de microrganismos produtores de novos compostos 
antimicrobianos é primordial no combate ao fenómeno mundial de resistência 
microbiana face aos antimicrobianos atualmente disponíveis. A natureza é uma 
fonte de diversos produtos, entre os quais se podem destacar os 
antimicrobianos. Os péptidos naturais podem ser sintetizados in vivo, por 
bactérias, através de vias metabólicas ribossomais ou não ribossomais. De 
destaque entre os péptidos antimicrobianos ribossomais produzidos por 
bactérias são as bacteriocinas. As bacteriocinas de classe I incluem os 
péptidos com modificações pós-traducionais, os lantipéptidos, que são 
caracterizados pela presença dos aminoácidos lantionina e metil-lantionina. Os 
lantipéptidos com atividade antimicrobiana designam-se lantibióticos. Estes, 
são capazes de  inibir o crescimento de  várias bactérias de Gram-positivo 
clinicamente relevantes como, por exemplo, Staphylococcus aureus resistente 
à meticilina. O trabalho desenvolvido teve como objectivo a procura/ pesquisa 
de novos antibacterianos, produzidos por bactérias isoladas em ambientes 
pouco comuns, nomeadamente, grutas e locais muito contaminados por metais 
pesados - minas de urânio e de ferro. 
Para tal, testou-se a atividade antibacteriana de 76 bactérias isoladas 
nos diferentes locais contra 12 estirpes indicadoras, de Gram-positivo e de 
Gram-negativo. Todos os isolados que apresentaram atividade foram 
classificados por sequenciação do gene 16S rRNA. Dentro deste grupo, foram 
selecionadas bactérias pertencentes aos filos Firmicutes e Actinobacteria para 
a realização de ensaios de produção de antimicrobianos em cultura líquida. De 
seguida, determinou-se a estabilidade proteolítica e térmica dos 
antimicrobianos produzidos por três estirpes de B. amyloliquefaciens (SL8, 
Sma1 e MO15). Atualmente, existem e estão depositados nas bases de dados 
13 genomas de B. amyloliquefaciens totalmente sequenciados. Assim, e 
utilizando a plataforma antiSMASH 2.0 procedeu-se à identificação de 
possíveis clusters de lantibióticos nesses genomas. Os genes biossintéticos de 
lantibióticos foram identificados apenas em três desses genomas; em dois 
desses genomas detectou-se o cluster de genes do lantibiótico mersacidina e 
no outro detectou-se a presença de um cluster ainda não caracterizado. Com 
base nessa informação, investigou-se a presença de genes característicos de 
operões biossintéticos de lantipéptidos nas estirpes SL8, Sma1 e MO15. O 
gene estrutural da mersacidina foi detectado nos três isolados. No entanto, o 
gene mrsM, que codifica para a enzima de modificação da mersacidina, 
apenas foi identificado nas estirpes SL8 e Sma1. Por outro lado, a amplificação 
de outra lanM não foi possível no isolado MO15. Foi ainda pesquisada a 
presença do péptido mersacidina, nos sobrenadantes das culturas líquidas 
destas estirpes, por MALDI-TOF/MS. Contudo, este lantibiótico não foi 
detectado em nenhum dos sobrenadantes. 
O presente estudo abre perspectivas para a identificação de lantibióticos 
nas estirpes em estudo. Por outro lado, outros estudos serão realizados 
envolvendo a pesquisa e caracterização dos compostos produzidos pelas 
restantes estirpes da coleção e que não foram exploradas nesta tese. 
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abstract 
 
Searching for new antimicrobials is crucial to address the phenomenon 
of microbial resistance to the most common antibiotics. Nature is a source of 
several products, namely antimicrobials. Natural peptides can be synthetized in 
vivo by bacteria through a nonribosomal or a ribosomal pathway. Among the 
ribosomal antimicrobial peptides produced by bacteria, the so-called 
bacteriocins are worth attention. Among these, the class I bacteriocins 
comprise the post-translationally modified peptides, designated lanthipeptides, 
which are characterized by the uncommon amino acids lanthionine and 
methyllanthionine. The lanthipeptides with antimicrobial activity are referred as 
lantibiotics. The lantibiotics are able to inhibit the growth of several clinically 
relevant Gram-positive bacteria, such as methicillin-resistant Staphylococcus 
aureus. This work aimed to search for new antibacterials produced by 
microorganisms isolated from uncommon sources, namely, caverns and heavy 
metal contaminated sites – uranium and iron mines. 
To that end, the antibacterial potential of 76 bacterial isolates from the 
different origins was investigated against 12 indicator strains, both Gram 
positive and Gram negative. All the isolates with antibacterial activity were 
affiliated by 16S rRNA gene sequence. Among these, bacteria belonging to the 
phyla Firmicutes and Actinobacteria were selected and included three Bacillus 
amyloliquefaciens - SL8, Sma1 and MO15. These isolates were investigated 
for antibacterial production assays in liquid culture. Supernatants with 
bioactivity were further investigated for proteolytic and temperature stability of 
the antimicrobial compounds produced. Presently, 13 genomes B. 
amyloliquefaciens are fully sequenced and assembled. Using the antiSMASH 
2.0 platform putative clusters for lanthipeptides were surveyed in all of these 
genomes and were found on three of the genomes only. Two of these clusters 
corresponded to the mersacidin and the other was uncharacterized. Thus, the 
presence of genes involved in the biosynthesis of lantibiotics was investigated 
in the three strains selected. It was found that SL8, Sma1 and MO15 isolates 
contain the mersacidin structural gene. However, the mrsM gene, which 
encodes the mersacidin modification enzyme, was only amplified in SL8 and 
Sma1 strains. Moreover, no other lanM was identified in the MO15 isolate. 
Therefore, the presence of the mersacidin peptide in culture supernatants was 
investigated by MALDI-TOF/MS. However, this lantibiotic was not detected in 
any of the three supernatants. 
The present work opens perspectives for the identification of lantibiotics 
produced by the strains studied. Also, other studies will be carried out to 
characterize the peptides produced by all the isolates of the bacterial culture 
collection constructed in the present study. 
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1.1 Natural products as a source of new antimicrobials 
Natural products are molecules derived from living organisms/natural sources that 
since early had incited investigators attention due to its useful applications in human 
welfare (Clardy and Walsh, 2004; Koehn and Carter, 2005). These biomolecules 
produced by plants, bacteria and fungi, have played important roles over the past century 
on medicine and front-line drug development, as they are a substantial source of bioactive 
compounds with pharmaceutical properties (Arnison et al., 2013; Koehn and Carter, 2005; 
Pickens et al., 2011). More specifically, natural products represent a pharmaceutically 
important class of compounds, that are sources of new therapeutic agents for bacterial 
and fungal infectious diseases, cancer and lipid disorders (lowering cholesterol levels) 
(Clardy and Walsh, 2004; Newman and Cragg, 2012). 
All the natural products are secondary metabolites that are produced by different 
species (not essential for growth) showing a wide range of chemical structures. Moreover, 
secondary metabolites are related to the ecology of the producing organisms, 
encompassing the interactions between the local communities, thus they can be 
considered  “molecules  of  adaptation” (Pickens et al., 2011; Verpoorte, 1998). 
Antibiotics are low-molecular-weight organic molecules produced by 
microorganisms that are particularly important for humankind (Demain, 1999). It is 
assumed that the antibiotic era started in 1928 with the discovery of penicillin by 
Alexander Fleming, when the first step for one of the great discoveries of the 20th century 
was given (Hassan et al., 2012; Stokes and Gillings, 2011). However,  antibiotics’  golden  
era lasted less than 50 years (Jan, 2003; Overbye and Barrett, 2005). During this period, 
antibiotics  were  used  massively   in  a  global  scale.  Antibiotics’   targets  are  bacteria,  which  
are known to adopt different strategies of antibiotic resistance, triggered by natural 
selection (Högberg et al., 2010; Livermore, 2003). Some of these mechanisms are the 
horizontal gene transfer, responsible for de acquisition of heterologous resistance (Lupo 
et al., 2012); and spontaneous mutations in the gene encoding   the   antibiotics’   target  
protein, which decreases antibiotics affinity (Hassan et al., 2012; Overbye and Barrett, 
2005). Antibiotic-resistant genes can also degrade the antibiotic enzymatically or exclude 
it out of the cell by a mechanism of transport (Hassan et al., 2012). The fact that these 
genes can be located in integrons and in mobile genetic elements such as plasmids and 
transposons, also enhance their dissemination (Livermore, 2003). 
Search for new lantibiotics 
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Owing to the emergence of this bacterial multiresistance phenomenon, bacterial 
infections considered controlled in the past, do not respond now to the typical treatments 
(Levy and Marshall, 2004). It has been considered a serious worldwide public health 
problem, leading scientific efforts to the discovery of new antimicrobials efficient against 
clinically relevant pathogenic microorganisms (Overbye and Barrett, 2005; Shenkarev et 
al., 2010). 
During the 20th century, many classes of natural products were discovered (Arnison 
et al., 2013). Among them, it is important to highlight a class of natural products produced 
by bacteria: the peptides with antimicrobial activity (Hassan et al., 2012). The biosynthesis 
of these peptides can be ribosomal (in which they can undergo post-translational 
modifications by biosynthetic enzymes) or independent of ribosomal translation (Figure 1). 
The bacterial peptides originated by the first pathway are called bacteriocins and the last 
ones are referred as nonribosomal peptides (NRP) (Nolan and Walsh, 2009). 
 
 
Figure 1 – Schematic representation of the ribosomal and nonribosomal biosynthetic peptide pathways 
(Caetano, 2011). 
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1.2 Nonribosomal peptides produced by bacteria 
The traditional peptide antibiotics are produced by the nonribosomal biosynthetic 
pathway through the action of multi-enzyme complexes designated as nonribosomal 
peptide synthetases (NRPS) (Nes et al., 2007). NRPS have a modular organization in 
which each module is responsible for the incorporation of one amino acid into the growing 
polypeptide chain. The modules are organized in domains, which are the catalytic 
enzymatic units of the individual NRP synthesis step. At least, each NRPS module 
comprises three different domains: the adenylation (A) domain that selects and activates 
the cognate amino acid as aminoacyl adenylate with ATP consumption; the peptidyl 
carrier protein (PCP) domain, which accepts the previously activated amino acid and 
transports it through the NRPS catalytic units; the condensation (C) domain, which 
catalyzes the formation of the peptide bond. A thioesterase (TE) domain is present at the 
termination module, which is responsible for releasing the final peptide from the NRPS 
(Figure 2) (Caetano, 2011; Finking and Marahiel, 2004; Schwarzer et al., 2003). The 
NRPS domains can be identified at the protein level by characteristic, highly conserved 
sequence motifs designated as core-motifs (Schwarzer et al., 2003). 
 
 
Figure 2 – Schematic  representation  of  the  NRPS’  modular  organization (Caetano, 2011). 
 
The NRPS are used concurrently as template (since the determination of the amino 
acid to be incorporated is performed by the module) and biosynthetic machinery (all 
necessary catalytic functions are ensured by the module) (Finking and Marahiel, 2004). 
The NRP can be modified by tailoring enzymes, including glycosyl transferases, 
halogenases and hydroxylases, which are usually encoded in the same biosynthetic gene 
cluster of the NRPS enzymes. This remarkable structural modifications lead to potent 
antibiotic activity, characteristic of the NRP (Nolan and Walsh, 2009; Walsh et al., 2001). 
Some NRP antibiotics can be used in the treatment of bacterial infections in 
humans, such as: penicillin, produced by the fungus Penicillium chrysogenum and 
Emericella nidulan (Brakhage et al., 2005); cephalosporin, produced by the fungus 
Acremonium chrysogenum (cephalosporin C) and by some Gram negative and positive 
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bacteria (Brakhage et al., 2005); vancomycin, produced by Amycolatopsis orientalis  
(Moellering and Ferraro, 2012) and daptomycin, from Streptomyces roseosporus (Figure 
3) (Steenbergen et al., 2005). Furthermore, the NRPS gene cluster can be manipulated to 
allow the generation of new drugs (Fortman and Sherman, 2005; Zhang et al., 2009). 
 
 
Figure 3 – Representation of examples of nonribosomal synthesized antibiotic peptides (Nolan and Walsh, 
2009). 
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1.3 Bacteriocins: ribosomally synthesized antimicrobial peptides from 
bacteria 
Bacteriocins are ribosomally synthesized antimicrobial peptides produced by 
various bacteria, which inhibit closely related or more distant species, acting as a 
bactericide or bacteriostatic agent (Begley et al., 2009; de Jong et al., 2006; Teng et al., 
2012). The mechanism of action of Gram-positive bacteriocins is quite effective since they 
are potent at pico- to nanomolar concentration (though its action spectra is limited at these 
concentrations) and specific, usually consisting on pore formation and/or inhibition of cell 
wall synthesis in target cells (Nissen-Meyer and Nes, 1997). These characteristics make 
bacteriocins promising antimicrobial agents suitable for being used as food preservative 
and infection treatment due to its competence in controlling antibiotic-resistant pathogens 
(Hassan et al., 2012). Gram-positive bacteria produce bacteriocins smaller than 6 kDa, 
while bacteriocins produced by Gram-negative bacteria are larger than 20 kDa, being 
colcidin V and microcins exceptions, since they are smaller than 10 kDa (Nissen-Meyer 
and Nes, 1997). It is also known that these antimicrobial peptides produced by Gram-
positive bacteria are non-toxic to eukaryotic cells and have broader spectra of action when 
compared to bacteriocins of Gram-negative bacteria (Nes et al., 2007). 
Initially, bacteriocins were classified into two main classes according to their post-
translational modifications: the class I, that comprises the modified bacteriocins or 
lantibiotics and the class II, that represents the unmodified bacteriocins (Nissen-Meyer 
and Nes, 1997). Currently, the bacteriocins are classified into five different classes based 
on various characteristics such as the producer microorganisms, mode of action, 
molecular weight, physical proprieties, chemical structures and specific antibacterial 
activity (de Jong et al., 2006): 
Class I: post-translationally modified bacteriocins, the lantibiotics; 
Class II: non-modified heat stable bacteriocins; 
Class III: non-modified large heat-labile bacteriocins; 
Class IV: non-modified complex bacteriocins carrying lipid or carbohydrate moieties; 
Class V: non-modified circular bacteriocins. 
This thesis will focus on class I, bacteriocins highly post-translationally modified and 
containing unusual amino acids in their composition - the lantibiotics (Guder et al., 2000). 
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1.4 Lantibiotics 
The interest on lantibiotics started in 1928, when nisin was first reported by 
presenting activity against Streptococcus lactis (now designated as Lactococcus lactis) in 
fementation cultures (Rogers and Whittier, 1928). During the last 60 years, nisin has been 
used commercially as food preservative (Cotter, 2012), since it presents activity against 
many pathogenic bacteria. Probably, the success of nisin in this area, along with its low 
stability at physiological pH, restricted the use of other lantibiotics in other fields such as 
the clinical setting (Cotter et al., 2005). However, the urgent need to find new and potent 
antibiotics has renewed the interest on these compounds as antibacterial drugs with broad 
clinical potential (Müller  et al., 2012). Lantibiotics can be potently active against several 
clinically relevant Gram-positive bacteria, such as antibiotic-resistant strains of 
Staphylococcus, including methicillin-resistant Staphylococcus aureus (MRSA), 
Streptococcus, Enterococcus, including vancomycin-resistant enterococci (VRE), 
Clostridium and oxacillin-resistant Gram positives, as well as against Gram-negative 
pathogens, such as Neisseria and Helicobacter (Cotter et al., 2005; Piper et al., 2009). 
Lantibiotics have various advantages when compared to the classical antibiotics: 
they are far more effective since their usual target is the essential cell wall precursor lipid 
II; their ribosomal (gene encoded) origin makes them more liable to bioengineering, 
leading to the creation of new lantibiotics derivatives with improved competences 
(Breukink and de Kruijff, 2006; Field et al., 2010). Although the development of resistance 
to lantibiotics is still unknown and the emergence of resistant bacteria is still a possibility, 
that might be minimized by peptide engineering and by a comprehensive study about 
lantibiotic mechanisms (Cotter et al., 2012; Shenkarev et al., 2010). 
Nowadays, there are various members of this family in clinical development, 
including duramycin for the treatment of cystic fibrosis (Grasemann et al., 2007) and a 
derivative of actagardine for Clostridium difficile infections (Knerr and van der Donk, 
2012). Moreover, the lantibiotic mutacin 1140 is presently in preclinical development for 
the treatment of infections caused by Gram-positive bacteria (Ghobrial et al., 2010). Some 
other  lantibiotics’  applications  are  being  developed,  including  in  agriculture  and  veterinary  
medicine (Cotter et al., 2012) and in molecular imaging (Zhao et al., 2008). 
The term lantibiotics derived from lanthionine (Lan)-containing antibiotics and this is 
a promising class of new antibacterial agents, which are small (< 5 kDa) bioactive 
polycyclic peptides characterized by the presence of uncommon amino acids such as 
thioether-linkage-containing meso-lanthionine (Lan) and (2S,3S,6R)-3-methyllanthionine 
(MeLan), as well as by various unsaturated amino acids such as 2,3-didehydroalanine 
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(Dha) and (Z)-2,3-didehydrobutyrine (Dhb) (Figure 4) (Nolan and Walsh, 2009; Teng et 
al., 2012). 
 
 
Figure 4 – Representation of the usual lantibiotic post-translational modifications. Abbreviations: Abu, 2-
aminobutyric acid; Dha, 2,3-didehydroalanine; Dhb, (Z)-2,3-didehydrobutyrineM Lab, labionin (Willey & van 
der Donk, 2007). 
 
Lantibiotics undergo post-translational modifications performed by lantibiotic 
synthetases, which are enzymes responsible for the formation of the uncommon amino 
acids mentioned before. These enzymes are notable catalysts that use macrocyclization 
as a critical strategy that allows an increased proteolytic and heat denaturation stability 
and also a better affinity of the peptides to their targets (Knerr and van der Donk, 2012; 
Willey and van der Donk, 2007). The first post-translational side-chain modifications are 
performed through the dehydration of serine and threonine residues. In this step, 
phosphorylation of the side-chain hydroxyl moieties of those amino acids occurs, which 
allows  the  cleavage  of  the  Cβ−O bonds by the elimination of the phosphate group (Figure 
5). This results in the conversion of serine and threonine residues into Dha and Dhb, 
respectively. Subsequently, a cyclase catalyses the intermolecular cyclization via a 
Michael-type addition: the dehydrate Dha and Dhb residues are intramolecularly and 
regioselectively captured by the side-chain thiol groups of the cysteine residues, 
establishing the thioether bridges Lan and Melan, respectively (Figure 6) (Knerr and van 
der Donk, 2012; Nolan and Walsh, 2009). 
 
 
Figure 5 - Representation the mechanism of dehydration in detail. Adapted from (Nolan and Walsh, 2009). 
 
Dehydration 
Search for new lantibiotics 
 
 10 
 
Figure 6 - Representation of the mechanism of Lan, MeLan and Lab (labionin) thioether cross-link formation, 
which are usual in mature lantibiotics (Willey and van der Donk, 2007). 
 
In general, lantibiotics are synthesized as a precursor peptide, the biologically 
inactive linear peptide with no amino acid modification that will yield the mature and active 
peptide. The precursor peptide comprises two regions: the N-terminal leader sequence 
(with 23-59 amino acids) and the C-terminal core peptide (Figure 7). The post-
translational modifications occur only in the core peptide of the precursor peptide (Nolan 
and Walsh, 2009; Teng et al., 2012; Willey and van der Donk, 2007). The leader peptide 
is an essential recognition element for the post-translational modification enzymes, 
immunity (as a self-protective mechanism) and export signaling (Oman and van der Donk, 
2010). Usually, the leader peptide is cleaved off by a specific protease during or after the 
exportation process through an ATP-binding cassette (ABC) transporter and the lantibiotic 
becomes biologically active (Figure 7) (Bierbaum and Sahl, 2009). 
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Figure 7 – General representation of ribosomally synthesized natural products (RNP) biosynthesis, common in 
lantibiotics biosynthesis. Xn represents a modified residue (Knerr and van der Donk, 2012). 
 
The genes involved in their biosynthesis are organized in clusters and encode 
information for the precursor peptide and all the enzymes responsible for modification 
(proteases and ABC transporters). Immunity factors and regulatory proteins might also be 
present in the lantibiotic gene cluster (Sahl and Bierbaum, 1998). These genes were first 
attributed with the generic designation lan followed by a capital letter. However, this 
designation can be replaced by a more specific nomenclature according to each lantibiotic 
genotype (e.g. nis for nisin, ltn for lacticin 3147, mrs for mersacidin, cin for cinnamycin, lch 
for lichenicidin). Considering the general nomenclature, the precursor peptide is encoded 
by the structural gene lanA, common to all gene clusters; the genes lanB, lanC, lanD, 
lanM and lanJ codify for the enzymes required for the post-translational modifications, 
lanP and lanT are responsible for proteolytic processing and lanT for the peptide 
transportation. Genes involved in regulation (lanR, lanK, lanQ and lanX) and in immunity 
(lanI, lanH and lanEFG) (Figure 8) (Guder et al., 2000; Nagao et al., 2006) are also 
present in the gene cluster. These gene clusters can be located on the chromosome of 
the producer (e.g. subtilin, mersacidin) or on mobile elementes such as conjugative 
transposons (e.g. nisin) or plasmids (e.g. epidermin, lacticin 481, lacticin 3147) 
(Chatterjee et al., 2005b; Nagao et al., 2006). 
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Figure 8 – Representative biosynthetic gene clusters of lantibiotics (Willey and van der Donk, 2007). 
 
In the last years, peptides without antibiotic activity, but possessing a biosynthetic 
strategy and structure similar to lantibiotics were discovered. As so, lantibiotics were 
integrated into a broader family of compounds named lanthipeptides (Goto et al., 2010). 
The non-lantibiotic lanthipeptides have different functions, including biosurfactant activity 
by decreasing the surface tension at the colony-air interface. This promotes the growth of 
vegetative hyphae during the sporulation of the producer bacteria (Knerr and van der 
Donk, 2012; Kodani et al., 2004; Kodani et al., 2005; Willey and van der Donk, 2007). 
Other example is labyrinthopeptin A2, which demonstrated a notable efficacy against 
neurophatic pain in an in vivo mouse model, being the first lanthipeptide discovered with 
this propriety (Knerr and van der Donk, 2012; Müller et al., 2010). This lanthipeptide is 
also characterized by the presence of labionin (Lab) (Figure 4, Figure 6, Figure 9), which 
is a carbacyclic, post-translationally modified amino acid resultant from the activity of the 
enzyme LabKC, in the motifs Ser-Xxx-Xxx-Ser-Xxx-Xxx-Xxx-Cys existent in the 
corresponding core peptides (Field et al., 2010; Meindl et al., 2010; Müller et al., 2010). 
 
 
Figure 9 – Structure of the labyrinthopeptin A2, a type-III lantibiotic (Müller et al., 2010). 
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 Classification of lantibiotics 1.4.1
Lanthipeptides are classified into four different classes based on their biosynthetic 
machinery (Figure 10) (Knerr and van der Donk, 2012). However, only the lanthipeptides 
of classes I and II display antibacterial activity (the lantibiotics), which are the main focus 
of this thesis. Thus, these two classes will be discussed in more detail in the following 
sections. 
 
 
Figure 10 - Representation of the two classes of lantibiotics based on the lanthionine-generating enzymes 
(Knerr and van der Donk, 2012). 
 
1.4.1.1 Class I  
The lantibiotics of class I are post-translationally modified by two different enzymes: 
the dehydratase LanB and the cyclase LanC (Figure 10) (Knerr and van der Donk, 2012). 
The most intensively studied class I lantibiotic is nisin, which has been used as food 
preservative during the last 60 years (Cotter, 2012). Nisin has important physiochemical 
properties such as the resistance to an acidic pH and high temperatures (Nagao, 2009). 
The study of its structure, biosynthetic gene cluster and mechanism of action provided a 
paradigm for the elucidation of these features on others lantibiotics (Nolan and Walsh, 
2009), promoting protein engineering (Müller  et al., 2012). 
The lantibiotic nisin is a flexible molecule with two amphiphilic domains, which 
consist of three lanthionine rings on its N-terminal (the A, B and C rings), two lanthionine 
rings on the C-terminal (the D and E rings) (Figure 11) and a flexible hinge region 
(between the C and D rings) that includes the residues Asn20, Met21 and Lys22 (Christ et 
al., 2007; Van Den Hooven et al., 1996). There are known four distinct forms of nisin, 
being three of them produced by Lactococcus lactis. Those three are nisin A (the 
prototype), nisin Z (differs one amino acid from the first one) and nisin Q (differs at four 
positions), having all of them 34 residues in length (Delves-Broughton et al., 1996). The 
other variant of nisin is nisin U (produced by Streptococcus uberis), which lacks the three 
residues at the C-terminal, sharing 78% of sequence similarity with nisin A (Wirawan et 
al., 2006). 
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Figure 11 - Structure of the class I lantibiotic nisin A (Willey and van der Donk, 2007). 
 
The nisin biosynthetic gene cluster is usually representative of class I lantibiotics. It 
has about 14 Kbp (Nolan and Walsh, 2009) and is located on a large conjugative 
transposon. This cluster is composed by eleven genes, which are involved in nisin 
biosynthesis, regulation and immunity (Nolan  and  Walsh,  2009;;  Trmčić  et al., 2011). The 
first operon consists of nisA, the structural gene of nisin A, which encodes the nisin 
precursor peptide, NisA, with 57 residues-long and includes the leader peptide of 23 
residues-long (Nolan and Walsh, 2009). This gene is separated from the following genes 
by an inverted repeat. A weak promoter precedes the immunity gene, which allows the 
expression of the immunity protein before the production of mature nisin. The fourth and 
last operon encodes the immunity proteins genes nisFEG (Figure 12) (Lubelski et al., 
2008). 
 
 
Figure 12 - Representation of the transcriptional organization of the biosynthetic gene cluster of nisin, a class I 
lanthipeptide. There are represented four separate transcriptional units. P* is referred to promoters controller 
by the two-component system NisRK and P corresponds to constitutive transcription (Lubelski, et al., 2008). 
 
The translation products of the lanB genes (nisB for nisin) are proteins of 
approximately 1000 amino acid residues that possess about 120 kDa of molecular weight, 
which do not show homology with any other known proteins (Chatterjee et al., 2005b; 
McAuliffe et al., 2001). Besides, the LanB family only shares 30% of sequence identity. 
The fact that those enzymes are rather hydrophobic in nature, associated with the 
presence of some hydrophobic domains, suggest they are associated with the 
cytoplasmic membrane (Chatterjee et al., 2005b). 
The LanC cyclases (NisC for nisin) are enzymes responsible for the cyclization 
reactions. They are about 400 residues long that share no sequence similarity with known 
proteins, having only 20%-30% sequence homology across the family (Knerr and van der 
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Donk, 2012). Nevertheless, they share some structural motifs in which the amino acids 
cysteine and histidine are conserved (McAuliffe et al., 2001). They are zinc 
metalloproteins with an active site composed by a Cys-Cys-His triad that function as 
ligands for zinc binding. This suggests a mechanism of action where zinc activates the 
thiol group of cysteine in order to proceed at the intramolecular nucleophilic attack to 
Dha/Dhb in the core peptide (Knerr and van der Donk, 2012; Okeley et al., 2003). It was 
also suggested a membrane location for these proteins (McAuliffe et al., 2001). 
After the modification of class I lantibiotics, an ABC transporter, LanT (NisT for 
nisin), exports the modified precursor peptide through the membrane and the maturation 
is complete when the leader peptide is cleaved in the extracellular medium by a subtilisin-
like serine protease, LanP (NisP for nisin) (Willey and van der Donk, 2007). The 
characteristics of these proteins are discussed below. 
The LanP proteases diverge in size due to the presence or absence of an N-
terminal sec-signal sequence and a C-terminal cell wall anchor sequence. However, all of 
them share homology with the serine protease subtilisin, mainly in the proximal sequence 
of the catalytic triad Ser-His-Asp and in the asparagine involved in oxyanion hole 
formation (Chatterjee et al., 2005b). Regarding the nisin protease (NisP), these residues 
were predicted to be Asp259, His306, Ser512 (van der Meer et al., 1993). The LanP proteins 
can be found either anchored to the cytoplasmic membrane or at the cytoplasmic side of 
the membrane. Though the proteolytic removal of the leader peptide is required for all 
lantibiotics biosynthesis, the genes encoding those proteases are not always present on 
the  lantibiotics’  gene  cluster,  suggesting  that  the  producer  strain  secretes  other  proteases  
that can also play this role (Chatterjee et al., 2005b). 
The LanT proteins (NisT for nisin) encoded in the biosynthetic gene clusters of class 
I lantibiotics are transmembrane ABC-transporters possessing 600 residues in length. The 
LanT transporters have the function to export the modified peptide of the cell (Knerr and 
van der Donk, 2012). These proteins share significant homology with hemolysin B-like 
ATP-dependent transport proteins, founded in a wide variety of organisms. They usually 
present three domains: a hydrophobic N-terminal domain, a six-helix crossing the 
cytoplasmic membrane and a C-terminal ATP-binding domain (Chatterjee et al., 2005b). 
However, as a typical ABC transporter includes four modules (two transmembrane 
segments and two nucleotide-binding domains), LanT is normally considered an ABC half-
transporter, which will most likely require another half-transporter to form an active unit. In 
the case of the lantibiotic nisin, two molecules of NisT (the ABC half-transporter for nisin) 
work together to form an active homodimer (Lubelski et al., 2008). Nevertheless, they 
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show relaxed substrate specificity, since NisT is competent on exporting unmodified nisin 
precursor peptide as well as unrelated peptides fused to the NisA leader sequence (van 
den Berg van Saparoea et al., 2008). This substrate promiscuity empowered the use of 
nisin biosynthetic machinery for in vivo bioengineering of various peptides with Lan and 
MeLan residues (Moll et al., 2010).  The  scheme  of  nisin’s  biosynthesis is represented in 
Figure 13. 
 
 
Figure 13 – Post-translational modifications of the lantibiotic nisin (Knerr & van der Donk, 2012). 
 
 Apart from nisin, the lantibiotics subtilin (produced by Bacillus subtilis), epidermin 
(produced by Staphylococcus epidermidis) and Pep5 (produced by Staphylococcus 
epidermidis strain 5) are also representative examples of class I (Figure 14) (Willey and 
van der Donk, 2007). Generally, these peptides have a more linear structure than those of 
class II. 
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Figure 14 – Structure of three representatives class I lantibiotics: subtilin, epidermin and Pep5 (Willey & van 
der Donk, 2007). 
1.4.1.2 Class II 
In class II, the precursor peptide is modified by a single bifunctional lantibiotic 
synthetase, LanM, which catalyzes both dehydration and cyclization reactions (Figure 10). 
The lacticin 481 (Figure 15), produced by several strains of Lactococcus lactis is usually 
used as an example of class II lantibiotic. Its biosynthesis begins with the transcription of 
the structural gene lctA (Figure 8), which encodes for a LctA precursor peptide with 51 
amino acids long (Xie et al., 2004). 
 
 
Figure 15 - Structure of the class II lanthipeptide lacticin 481 (Willey and van der Donk, 2007). 
 
The LanM proteins (LctM for lacticin 481) are large polypeptides with usually 900-
1200 residues in length and about 120 kDa (Knerr and van der Donk, 2012; You and van 
der Donk, 2007). These enzymes contain two domains: the N-terminal dehydratase 
(sharing no homology with LanB) and the C-terminal LanC-like cyclase (having about 25% 
of sequence similarity to LanC). The C-terminal (more specifically the LanC-like cyclase 
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domain) also presents the zinc-binding residues essential for NisC cyclase activity (Figure 
10). As it occurs with LanB and LanC, LanM proteins do not share high sequence identity 
across their own family (Knerr and van der Donk, 2012; Li and van der Donk, 2007; Willey 
and van der Donk, 2007). A mutation of the cysteine ligands to the zinc in LctM eradicates 
the correct macrocyclization reactions, though the dehydration reactions are not affected 
(Knerr and van der Donk, 2012; Paul et al., 2007). 
The in vitro reconstitution of the LctM revealed that this enzyme requires ATP and 
Mg2+ to perform the phosphorylation reaction of serine and threonine residues. 
Subsequently, LctM eliminates the resulting phosphate ester, forming Dha and Dhb, 
respectively (Figure 16 a) (Chatterjee et al., 2005a). It was also known that ADP and Mg2+ 
must be bound to the active site during the phosphate elimination reaction (You and van 
der Donk, 2007). 
 
 
Figure 16 – Proposed mechanisms of serine/threonine dehydration (a) (Knerr and van der Donk, 2012) and 
cyclization (b) (Paul et al., 2007) by the lacticin 481 synthetase, LctM. 
 
The dehydration and cyclization reactions of LctM are independent. A proposed 
model defends that the cyclization begins when the zinc activates the thiol groups of 
cysteine residues for nucleophilic attack. It was also reported the existence of an active 
site base and acid involved in deprotonation of the thiol groups and protonation of the 
enolate intermediate, respectively (Figure 16 b). The conserved His725 is important but not 
mandatory for the correct cyclization of the precursor peptide (Paul et al., 2007).The 
preference of performing the intrinsic cyclization of Dha over Dhb demonstrates the 
notable regioselectivity of lanthipeptide cyclases (Knerr and van der Donk, 2012; Zhang et 
al., 2007). 
The LanT enzymes of class II lantibiotics present about 700 residues long (they are 
100 residues longer than class I) and, besides the membrane spanning and C-terminal 
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ATP-binding domains, they contain a conserved N-terminal domain: the papain-like 
cysteine protease domain (Chatterjee et al., 2005b). These multifunctional enzymes 
perform the secretion and the leader processing (Willey and van der Donk, 2007). The 
protease domain of LanT is able to cleave both unmodified and LctM-modified LctA, which 
demonstrates a relaxed substrate specify. However, the leader cleavage site seems 
constant: the double-glycine-type cleavage site is conserved in class II lantibiotics, where 
processing occurs (Chatterjee et al., 2005a; Furgerson Ihnken et al., 2008). The ABC 
transporter domain is not necessary for LanT protease activity, being proposed to play a 
role in a more specific substrate recognition (Knerr and van der Donk, 2012). A general 
scheme of the biosynthesis of lantibiotic lacticin 481 is represented in Figure 17. 
 
 
Figure 17 – Representation of post-translational modifications involved on the biosynthesis of the lantibiotic 
lacticin 481 (Knerr and van der Donk, 2012). 
 
 Some other representative class II lantibiotics include cinnamycin (produced by 
Streptomyces cinnamoneus) (Widdick et al., 2003), mersacidin (produced by Bacillus sp. 
strain HIL Y-85,54728) (Altena et al., 2000) (Figure 18), duramycin (produced by 
Streptomyces cinnamoneus), duramicin B (produced by Streptoverticillium sp.) and 
duramycin C (produced by Streptomyces griseoluteus) (Guder et al., 2000; Willey and van 
der Donk, 2007). 
 
 
Figure 18 – Structures of representative examples of Class II lantibiotics: cinnamycin, lacticin 481 and 
mersacidin  (Willey and van der Donk, 2007). 
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The two component lantibiotics (e.g. haloduracin, lichenicidin) are a special group of 
this class (Willey and van der Donk, 2007) that will be described in the next section. 
1.4.1.3 Two-component lantibiotics 
The biosynthesis of the two-component lantibiotics follows the general mechanism 
of those from class II (Caetano et al., 2011). However, they are constituted by two 
structurally different peptides that show broader biological activity when acting in synergy 
(Shenkarev et al., 2010). This group comprises cytolysin L, haloduracin, lacticin 3147 and 
lichenicidin, among others (Figure 19) (Knerr and van der Donk, 2012; Willey and van der 
Donk, 2007). 
The unmodified precursor peptides (LanA1 and LanA2) are encoded by individual 
structural genes (lanA1 and lanA2) and are enzymatically modified to their mature and 
bioactive forms (Lanα and Lanβ,   respectively) by separate LanM enzymes (LanM1 and 
LanM2, respectively) (Oman and van der Donk, 2009; Willey and van der Donk, 2007). 
The structures of the mature α-peptides resemble the lantibiotic mersacidin, because of its 
globular structure, with several thiother rings, while the β-peptides are usually more 
elongated and flexible (Figure 19) (Martin et al., 2004; Oman and van der Donk, 2009). 
The  sequence  homology  among  α-peptides and mersacidin, more specifically the three C-
terminal rings, suggest they are important motifs for lipid II binding (Willey and van der 
Donk, 2007). The modification process is complete when a single multifunctional protein, 
LanT, which contains an ABC transporter and a protease domain, removes the leader 
sequence and secretes both biologically active peptides (Caetano et al., 2011; Oman and 
van der Donk, 2009; Willey and van der Donk, 2007). 
 
 
Figure 19 - Structures of representative examples of two-component lantibiotics, a class II lantibiotics' group 
(Willey and van der Donk, 2007). 
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As an example of the two-component lantibiotics is lichenicidin, that is produced by 
the Gram positive endospore-forming Bacillus licheniformis, and inhibits growth of other 
Gram positive bacteria (Mendo et al., 2004). This lantibiotic was discovered in Bacillus 
licheniformis ATCC 14580 through a genome mining approach, using the bioinformatic 
tool BAGEL2 (Begley et al., 2009; de Jong et al., 2010). Its biosynthetic gene cluster 
comprises all the genes necessary for its synthesis, regulation and immunity of the 
producer (Figure 20) (Caetano et al., 2011; Dischinger et al., 2009). 
 
 
Figure 20 - Representation of the lichenicidin biosynthetic gene cluster, according to the genome annotation 
for Bacillus licheniformis ATCC 14760 (Caetano et al., 2011). 
 
Lichenicidin presents antimicrobial activity against MRSA and Listeria 
monocytogenes when the two mature peptides (Bliα and Bliβ)  are  produced  (Figure 21). 
However, a study proved that, if only one of the peptides is produced, the antibacterial 
activity can be re-established by external supply through cross-feeding with the 
complementary missing peptide (Caetano et al., 2011). 
 
 
Figure 21 - Structure  of  the  mature  lichenicidin  peptides,  Bliα  and  Bliβ (Caetano et al., 2011). 
 
 Mode of action of lantibiotics 1.4.2
The   lantibiotics’   mode   of   action   consists   mainly   in   two   possibly   cell   target:   the  
cytoplasmic cell membrane and the essential cell wall precursor lipid II (Bierbaum and 
Sahl, 2009). For instance, the class I lantibiotic nisin is characterized by a dual mode of 
action, employing its activity on both targets mentioned by interfering with the cell wall 
biosynthesis and affecting the integrity of the cytoplasmic membrane (Wiedemann et al., 
2001). 
The cell wall is an important barrier for bacteria survival, which is composed by a 
strong extracellular peptidoglycan matrix, resistant at the high osmotic pressure of the 
cytoplasm. The peptidoglycan is constituted by monomeric units that are the building 
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blocks of the cell wall. The monomeric peptidoglycan consists of two amino sugars, N-
acetylglucosamine (GlcNAc) and N-acetylmuramic acid (MurNAc), and a pentapeptide 
usually L-Ala-D-γ-Glu-L-Lys-D-Ala-D-Ala attached to the carboxyl group of MurNAc. 
These subunits are founded attached with an undecaprenyl phosphate carrier (a 
membrane-anchoring) and all together form the lipid II (Figure 22). The lipid II is 
transported for the extracellular domain where it accomplishes the polymerization of the 
peptidoglycan moiety (Hsu et al., 2004). 
 
Figure 22 - Structure of the cell wall precursor Lipid II (Wiedemann et al., 2001). 
 
Studies demonstrated that nisin binds first to a lipid II, which serves as a docking 
molecule   for   this   lantibiotic’s   activity:   the   two   N-terminal rings of nisin form a binding 
pocket (also called the pyrophosphate cage) that encloses the undecaprenyl 
pyrophosphate moieties of lipid II (Bierbaum and Sahl, 2009). The contact between the 
nisin and lipid II is performed through the A and B ring of nisin, which are conserved in 
other class I lantibiotics, including microbisporicin and mutacin 1140 (Knerr and van der 
Donk, 2012). This binding pocket is stabilized by hydrogen bonds involving the residues 
Dhb2 Ala3 Ile4 Dhb5 and Abu8 (Hsu et al., 2004). The next step involves the C-terminus of 
nisin, which inserts into the membrane, oligomerizes and forms a pore constituted by eight 
molecules of nisin and four molecules of lipid II (Figure 23) (Breukink et al., 2003; Hasper 
et al., 2004). When nisin binds to lipid II, the peptidoglycan biosynthesis is inhibited by 
physical sequestration, preventing the actions of transglycosylases (enzymes that 
polymerize lipid II) and transpeptidases (enzymes that crosslink the glycan chains of the 
emerging cell wall) (Breukink and de Kruijff, 2006; Oman and van der Donk, 2009). 
 The flexible hinge region of nisin (residues 20-22) is fundamental for the pore 
formation. This causes a collapse of the vital ion gradients across the membrane and also 
induces a rapid efflux of cytoplasmic solutes such as amino acids and nucleotides. The 
simultaneous cytoplasmic membrane depolarization results in the immediate terminus of 
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all biosynthetic processes, including the cell-wall synthesis (Wiedemann et al., 2001). This 
unique mode of action makes nisin a vey potent bactericidal agent at nanomolar 
concentrations, against closely strains related to its producers, including Streptococci, 
Staphylococci, Enterococci and drug-resistant bacteria such as MRSA and VRE (Nagao, 
2009). 
 
 
Figure 23 – Representation of a proposed model for lipid-II mediated pore formation by the lantibiotic nisin. 
The present arrangement of the pore structure is speculative (Chatterjee et al., 2005b). 
 
Some class I lantibiotics, including the lantbiotic epidermim, produced by 
Staphylococcus epidermidis Tü 3298 and the lantibiotic gallidermin, produced by 
Staphylococcus gallinarum Tü 3928 (Bonelli et al., 2006) bind with high affinity to lipid II, 
through their N-terminal, and kill bacteria without permeabilizing the membrane, meaning 
they act without the formation of pores. This is explained by the existence of another lipid 
II mediated mechanism of cell inactivation (Hasper et al., 2006; Islam et al., 2012). These 
lantibiotics have the ability to sequester the lipid II from its functional to non-functional 
locations, conducting to the terminus of the cell wall synthesis (Islam et al., 2012; de 
Kruijff et al., 2008). 
The class II lantibiotic mersacidin exerts its biological functions by binding to lipid II 
and inhibiting transglycosylation (and, consequently, the cell wall biosynthesis) through a 
Ca2+-dependent mechanism, without forming pores (Böttiger et al., 2009; Knerr and van 
der Donk, 2012). 
Considering the class II two-component lantibiotics, such as lacticin 3147, 
lichenicidin and halorudacin, their two structural peptides display low activity individually, 
but when they interact synergistically, they show potent antibiotic activity at nanomolar 
concentrations (Knerr and van der Donk, 2012; Shenkarev et al., 2010). Their mode of 
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action   is  usually  exemplified  by   the   lacticin  3147   (Ltnα  and  Ltnβ  peptides),  which  has  a  
dual   mode   of   action.   The   α-peptide binds to the lipid II (inhibiting peptidoglycan 
biosynthesis) and a part of this peptide is partially inserted into the membrane bilayer. 
Subsequently,  a  conformational  change  in  the  Ltnα  occurs,  Ltnβ  recognizes  and  binds  to  
the complex previously formed and inserts into the cytoplasmic membrane, leading to an 
efficient pore-formation and cell death (Figure 24) (Piper et al., 2009; Wiedemann et al., 
2006). It   is   also   known   that   the   α-peptide of lacticin 3147 and halorudacin shares the 
mersacidin-lipid II binding motif (Knerr and van der Donk, 2012). 
 
 
Figure 24 - The dual mode of action of the two-peptide  lantibiotic  lacticin  3147.  The  α  peptide  (Ltnα)  binds  to  
the lipid II and is partially inserted into the membrane (1.).  This  triggers  a  conformational  change  in  the  Ltnα  
and  the  β  peptide  (Ltnβ)  binds  to  the  complex formed, allowing pore formation and rapid cell death (2.) (Piper 
et al., 2009). 
 
Nevertheless, not all lantibiotics act exclusively as antimicrobial agents. For 
instance, cinnamycin and related duramycins are potent inhibitors of phospholipase A2 
(Märki et al., 1991; Willey and van der Donk, 2007). Besides, duramycin can also increase 
the chloride secretion in lung epithelium (Cloutier et al., 1990); hence, as mentioned 
before, duramycin has been clinically tested in order to evaluate its efficacy in clearing 
mucus secretions from the lungs, state associated with cystic fibrosis and other airway 
diseases (Grasemann et al., 2007; Willey and van der Donk, 2007). Recently, it was 
discovered that duramycin may exhibit antiproliferative properties and induces apoptosis 
in tumoral cells (Yates et al., 2012). 
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1.5 In silico analysis in the discovery of new natural products 
Natural products or secondary metabolites have radically improved human life 
quality. With the increased of longevity combined with the emerging antibiotic resistant 
pathogens and infectious diseases, there is an urgent need to discover new therapeutic 
agents (Winter et al., 2011). 
The classical approach for natural products discovery usually includes rigorous 
screening tests of crude extracts naturally produced by fungi and bacteria. Subsequently, 
a bioassay-guided fractionation or chemical screenings is performed for the final structure 
elucidation. Despite being favorable in the past, this approach is now unfeasible due to 
the high discovery rates of new natural products (Winter et al., 2011). 
The research in natural products field has experienced a significant decline during 
the last decades. However, many efforts have been undertaken in order to controvert that 
situation. These efforts, including whole-genome sequencing projects, metagenomic 
approaches and genome studies of microorganisms from extreme and unusual habitats, 
proved that the natural products field was initially undervalued, presenting instead an 
immensity of unexplored therapeutic potential (Winter et al., 2011). The genome 
sequencing projects provided an impressive genetic data available, which can be deeply 
exploited by genome mining. The in silico genome mining approach associated with the 
bioinformatics tools, allows the detection of cryptic or silent biosynthetic pathways for 
metabolites never detected before, resulting in the discovery of new natural products. 
Based on known paradigms of secondary metabolite biosynthesis, it is also possible to 
discover new natural products and isolate the respective biosynthetic gene clusters. 
Furthermore, the heterologous expression of genetic data from difficult to manipulate 
strains or uncultured organisms has also contributed to the discovery of novel natural 
products, either by the identification of gene clusters, or by simplifying genetic 
manipulation of the target gene. Finally, and probably most importantly, the constant 
discovery of novel biosynthetic enzymes contributes to a constant update of the features 
inherent in natural product biosynthesis (Van Lanen and Shen, 2006). 
According to the main theme of this work, the lantibiotics, automated in silico 
genome mining and annotation software approaches have been extremely useful for the 
discovery of novel compounds of this family (Knerr and van der Donk, 2012; Marsh et al., 
2010). The availability of this genomic information has already led to the identification of 
the class I epidermin-like lantibiotic, Bsa (produced by Staphylococcus aureus) (Daly et 
al., 2010), the class II lantibiotics haloduracin (produced by Bacillus halodurans C-125)  
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(McClerren et al., 2006) and lichenicidin as well as various cyanobacteria-associated 
lanthipeptides (Li et al., 2010; Marsh et al., 2010). 
In this context, it is important to highlight three bioinformatics tools for in silico 
identification of secondary metabolites, which have already been used in lantibiotic-
context: BAGEL (de Jong et al., 2006), BACTIBASE (Hammami et al., 2007) and 
antiSMASH (Medema et al., 2011). 
The BAGEL (BActeriocin GEnome mining tooL) is a specific bioinformatics tool that 
enables the identification of bacteriocins and respective biosynthetic gene clusters. The 
ORF (open reading frames) detection makes BAGEL independent of GenBank 
annotations, allowing the access of bacteriocin genes (usually, small genes) that probably 
would be omitted in the annotation process of bacterial genomes deposited on GenBank. 
The BAGEL results are also based in motifs databases. All of these innovations turn 
BAGEL into a promising bacteriocin cluster detector in (new) bacterial genomes (de Jong 
et al., 2006). An improved version was recently released, BAGEL2, which allows high-
throughput screening capable of dealing with the increasing genomic data sets and also a 
large input data set (>1000 genomes), in order to optimize bacteriocin identification (de 
Jong et al., 2010). 
The BAGEL lacks information based on protein properties. Thus, a new and original 
database named BACTIBASE appeared in 2007. This database contains calculated or 
predicted physicochemical properties of bacteriocins produced by both Gram positive and 
Gram negative bacteria, allowing a rapid and comprehensive structural and functional 
analysis (Hammami et al., 2007). An improved version was released on 2010, which 
contains an expanded number of entries and diverse tools, including multiple sequence 
alignment and homology search (Hammami et al., 2010). 
The bioinformatic tool antiSMASH (antibiotics & Secondary Metabolite Analysis 
Shell) allows the search of natural product biosynthetic gene cluster from the whole 
genomes deposited. Then, it is possible to predict both the substrate selection and the 
structure of the associated product (Winter et al., 2011). In fact, this database is capable 
of identifying biosynthetic loci, covering all known secondary metabolites classes, 
including  the  lantibiotics’  family.   In  this  context,  antiSMASH  is  an  advantageous  tool  that  
encompasses diverse bioinformatics analysis, providing a very high accuracy in its 
individual cluster annotations (Medema et al., 2011). The three bioinformatic tools 
mentioned might be used in consortium in order to obtain a more complete and detailed 
information. 
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The genome mining approaches usually take advantage of the highly conserved 
nature of lantibiotic biosynthetic enzymes. For instance, an in silico screen for class II 
lantibiotics (lanM genes) resulted in the identification of 61 novel lantibiotic (Begley et al., 
2009). Additionally, an in silico screen for lanC genes allowed the identification of 49 novel 
class I lantibiotic gene clusters associated with species, genera and even phyla of 
bacteria which have never been associated with the production of this compounds, 
including the thermophilic Geobacillus, a source of thermostable enzymes with industrial 
interest. All of these new gene clusters are extremely valuable as they can yield an 
immensity of novel antimicrobials and biosynthetic enzymes (Marsh et al., 2010), 
enhancing the impact of the bioinformatics tools alongside with in silico approaches. 
1.6 Objectives 
The emergence of new multiple drug-resistant pathogenic bacteria has been a 
global health problem. So, the discovery of new and highly active molecules against these 
bacteria represents a major goal. 
Thus, the main objectives of this thesis, were: 
x Screening for antibacterial activity of bacterial isolates from different 
environments; 
x Identification and selection of the strains with an interesting spectrum of 
activity; 
x Identification of potential biosynthetic clusters encoding for lantibiotics. 
 

  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 Results and Discussion 
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2.1 Selection of bacteria producing antibacterial compounds 
The bacterial isolates of this study were firstly characterized by performing a 
phenotypic screening for antimicrobial activity against relevant indicator bacterial strains. 
In this screening, 76 bacteria were tested against 12 indicator strains (Table 4) using 
colony bioassay methodologies. With this approach, a total of 58 bacteria (76,3 % of the 
isolates) showed inhibitory activity at least against one indicator strain. The sequence of 
the 16S rRNA gene of these isolates was analyzed, allowing their division into three main 
groups: 27,6% belong to the phylum Firmicutes, (Figure 27), 22,4% to the phylum 
Actinobacteria (Figure 26) and 50,0 % were Gram-negative bacteria (Figure 25) of the 
phyla Proteobacteria (44,8%) and Bacteroidetes (5,2%). 
In a general overview, the Gram-negative bacteria were the less affected by the 
isolates tested. For instance, it was not possible to detect a clear antibacterial activity 
against Pseudomonas aeruginosa or Klebsiella pneumonia indicator strains. In fact, 
Gram-negative bacteria are normally less permeable to antibiotics than Gram-positive 
microorganisms. This is mostly due to its outer membrane, which function as a barrier to 
the entrance of compounds (Sr and Rao, 2012). Besides that, Gram-negative bacteria can 
repeal, for instance, cationic peptides with antimicrobial activity by reducing the net 
negative charge of this outer membrane (Koprivnjak and Peschel, 2011). 
The Gram-positive isolates under study yield antibacterial products effective against 
a major range of Gram-positive and Gram-negative indicator strains than Gram-negatives. 
Thus, only isolates belonging to Actinobacteria and Firmicutes phylum were selected for 
further discussion. Generally, the Actinobacteria isolates showed activity mostly after 72 h 
and 1 week of inoculation in solid medium trypic soy agar (TSA), whereas the Firmicutes 
were mainly active after 24 h and 48 h of incubation (Figure 26 and Figure 27). Though, 
the results obtained for these two phyla were discussed in more detail in the following 
sections. 
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Figure 25 – S
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Figure 27 - Spectrum
 of antibacterial activity of Firm
icutes identified by 16S
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 gene sequencing, using agar-based bioassays 
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 Antibacterial activity of Actinobacteria isolates 2.1.1
The phylum Actinobacteria comprises most of the Gram-positive organisms with a 
high G+C content (Gao and Gupta, 2012). This phylum has been intensely studied due to 
its biotechnological potential. It is an important class of microorganisms for drug 
discovering, as approximately 70% of antibiotics available in market were obtained from 
soil Actinobacteria (Monaghan and Barrett, 2006; Sr and Rao, 2012). Moreover, 
Actinobacteria members produce an immensity of other secondary/specialized 
metabolites with important biological activities such as antitumor and anti-infection agents, 
plant-growth promoters and enzymes (Qin et al., 2011). In this study, the most active 
Actinobacteria  isolates  were  VT1,  AR1,  αA,  M1  and  NL9,  as  they  inhibited  (clearly  or  less  
clearly) at least 6 indicator strains, including Gram-negatives (Figure 26). 
The isolates VT1, AR1 (both from caves in Portimão) and M1 (from Cunha Baixa) 
were identified as belonging to Streptomyces genus and they had a similar inhibition 
spectrum. All of them were effective against the Gram-positives Enterococcus faecalis 
ATCC 29212, Haemophilus influenzae 121642, Listeria monocytogenes 71, Micrococcus 
luteus ATCC 9341 and Staphylococcus aureus ATCC 29213. Moreover, they also showed 
antibacterial activity (although reduced) against the Gram-negative Salmonella enteretidis 
ATCC 13076. Some differences were detected among the inhibition spectra of these 3 
isolates: M1 was the only Actinobacteria isolate that inhibited Enterococcus faecium 
547261; VT1 and M1 had the capability of Bacillus cereus Av2 inhibition and VT1 was 
able to partially inhibit Pseudomonas aeruginosa PAO1 (Figure 26). 
Streptomyces are soil filamentous bacteria, which experience a complex process of 
morphological differentiation. It is known that this genus can produce an immensity of 
secondary products, many of which with antibiotic or other pharmacologically useful 
activities (Pang et al., 2004). Moreover, they are also lanthipeptide-producers, being SapB 
(produced by Streptomyces coelicolor) the best well characterized (Kodani et al., 2004). 
The   bacterial   isolates   αA   and   NL9   were   classified   as   belonging   to   the genus 
Microbacterium. The Microbacterium organisms are Gram-positive, aerobic and rod-
shaped bacteria. They can be isolated from diverse environments, such as environmental 
sources, clinical patients (Funke et al., 1995), pork sausage (associated with its flavor 
deterioration) (McLean and Sulzbacher, 1953) and radioactive sites (Bendiks et al., 2013; 
Nedelkova et al., 2007). Although αA  and  NL9  presented  a  broader   inhibition  spectrum,  
most  of  the  results  were  detected  as  a  partial  inhibition.  In  this  way,  αA  had  a  clear  effect  
against the Gram-positives L. monocytogenes and B. cereus. The partial inhibitions 
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corresponded to the Gram-positives E. faecalis, H. influenzae, M. luteus and S. aureus; 
and to the Gram-negatives Aeromonas hydrophila ATCC 7966 and S. enteretidis. The 
NL9 isolate presented the same activity against the Gram-positive   indicators   as   αA,  
though its antimicrobials were partially effective against the Gram-negatives P. aeruginosa 
and A. hydrophila (Figure 26). So far, there are no descriptions regarding the identification 
of antibacterial compounds produced by Microbacterium spp. isolates. Studies involving 
this genus are normally focus to identification and description of species. 
 Antibacterial activity of Firmicutes isolates 2.1.2
Firmicutes are known as Gram-positive bacteria with low G + C content and some 
of them are characterized by endospore formation (Onyenwoke et al., 2004). The most 
active isolates belonging to this genus were αB, SL8, SL9, SL10, Sma1 and MO28, as 
they inhibit the greater number of Gram-positive and Gram-negative indicator strains. 
The isolate αB belong to the Paenibacillus genus, a Gram-positive endospore-
forming bacteria (Lorentz et al., 2006). Strains of Paenibacillus have been identified in 
several environments, including soils (Berge et al., 2002), water, rhizosphere and hospital 
clinical material (Bosshard et al., 2002; Lorentz et al., 2006). In this way, was not 
surprising the isolation of this strain from soil samples. The αB isolated was able to inhibit 
the Gram-positives H. influenzae, L. monocytogenes and M. luteus; and, with lower 
intensity, the Gram-negatives E. coli, Klebsiella pneumoniae, P. aeruginosa and 
Salmonella enteritidis (Figure 27). 
The bacteria SL8, SL9, SL10, Sma1 and MO28 were identified as Bacillus spp. 
isolates. The elements of this genus are Gram-positive, aerobic and endospore-forming 
bacteria with a ubiquitous distribution. In fact, they can be found in soils, rocks, dust, 
aquatic environments, vegetation, food as well as in the gastrointestinal track of several 
insects and animals (Abriouel et al., 2011; Nicholson, 2002). They are normally an 
interesting source of secondary metabolites with distinct activities and structures. These 
metabolites include antibiotics, antifungals, growth promoters for animals and plants, 
enzyme inhibitors and other bioactive compounds that constitute an evolutive advantage 
for their survival in its natural environment (Stein, 2005). For instance, Bacillus subtilis can 
produce more than 24 antibiotics with different structures, being the peptide antibiotics the 
most prevalent class (Chaabouni et al., 2012; Stein, 2005). Some of this peptides are 
lantibiotics, the class I and class II lanthipeptides possessing antibacterial activity 
(Abriouel et al., 2011). Based on that, the genus Bacillus has been widely investigated 
due to the potential application of its products in the agriculture, food and pharmaceutical 
Search for new lantibiotics 
 
 38 
industries, in order to prevent/control spoilage and pathogenic microorganisms 
(Chaabouni et al., 2012; Motta et al., 2007). Similarly to metabolites from lactic acid 
bacteria, several products from Bacillus are generally recognized as safe (GRAS) 
(O’Sullivan   et al., 2002). This status was firstly approved for B. coagulans strain 
GanedenBC30. Actually, some Bacillus are used as probiotics for human, veterinary and 
aquaculture use (Cutting, 2011). Moreover, Bacillus-based probiotics are also being 
developed for use as plant growth promoters (Chaabouni et al., 2012). 
The bacteria SL8, SL9 and SL10 were isolated from the same sampling point 
(Cunha Baixa) and were effective against the same indicator strains: E. faecium, H. 
influenzae, L. monocytogenes, M. luteus, S. aureus and B. cereus; and the Gram-
negative E. coli and A. hydrophila, however when incubated for different times (Figure 27). 
Among all Firmicutes, the Sma1 bacteria showed the most interesting spectrum of 
inhibition. This isolate was partially active against P. aeruginosa and totally active against 
all the other indicator strains, except S. aureus and K. pneumoniae. 
2.2 Selection of bacteria for production of antibacterial compounds in 
liquid medium 
It is known that the production of antibacterial compounds in agar-based medium is 
not always accomplished using the equivalent liquid medium (Compaoré et al., 2013). 
Thus, in this present study, the bacteria with the most interesting spectrum of activity were 
selected to investigate the production of these secondary metabolites also in liquid 
medium. In this context, only the Actinobacteria and Firmicutes isolates were considered. 
However, the number of strains to be tested in liquid medium was reduced, based on the 
genus, similar spectrum of activity and finally rep-PCR fingerprinting (by ERIC and BOX-
PCR). In this molecular analysis, isolates differing at least in one band with either of the 
two reactions performed were considered different strains. Thus, the Firmicutes tested in 
liquid   medium   were   SL1,   SL3,   SL8,   SL11,   αB,   Sma1,   NL8,   MO15,   MO22,   MO27   and  
MO31 isolates, whereas the Actinobacteria isolates tested were POR6, POR15(1), VT1, 
VT4,  AR1,  AR9,  LA1,  αA,  M1,  NL9,  NL11  and  MO23. 
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 Production of antibacterial compounds in liquid medium 2.2.1
In this bioassay, Firmicutes and Actinobacteria isolates were grown in trypic soy 
broth (TSB) liquid medium over a week period at 26 ºC. This assay aimed to verify if the 
antibacterial agents produced by agar-based colony bioassay were released into the 
culture supernatant and to determine the corresponding inhibitory spectra. Thus, the 
activity of the cell-free supernatants (CFSs) from 22 different isolates was tested against 
all the 12 indicator strains used in this study. The production of antibacterial compounds 
was tested after 24 h, 48 h, 72 h and 1 week (168 h) of incubation, using three replicas. 
The results showed that the CFSs of 13 isolates  (αA,  αB,  NL11,  MO27,  AR9,  NL9,  SL11,  
NL8, POR6, LA1, VT4, AR1 and MO23) did not inhibit any of the indicator strains. Then, 
only 9 strains were effective against at least one indicator strain (Figure 28 and Figure 
29). 
Overall, higher inhibition areas were observed with Gram-positive indicator strains 
(E. faecalis, E. faecium, H. influenzae, L. monocytogenes, M. luteus and S. aureus), as it 
was also observed for colony bioassay (Figure 28). This could be due to the composition 
of the cell wall of Gram-positive bacteria, which lacks an outer membrane. Regarding the 
Gram-negative indicators, P. aeruginosa was not inhibited by any of the tested CFSs, 
whereas A. hydrophila was the indicator with most prominent inhibition halos (about 4 
mm) (Figure 29). Moreover, none of the CFSs from Actinobacteria (POR15(1), VT1 and 
M1) were able to affect the growth of the Gram-negative bacteria. 
Based on all information from CFSs bioassay, SL8, Sma1 and MO15 had the 
broadest spectra of inhibition as, when cultivated in liquid medium, they were active 
against 11 from a total of 12 different indicator bacteria, including Gram-positives and 
Gram-negatives (E. faecalis, E. faecium, H. influenzae, L. monocytogenes, M. luteus, S. 
aureus, B. cereus, E. coli, K. pneumonae, A. hydrophila and S. entereditis). For these 
isolates, the maximum inhibition was generally observed after 48 h of incubation (Figure 
28). On the other hand, the CFSs collected after 72 h were completely inactive against all 
the Gram-negatives, except A. hydrophila (Figure 28 and Figure 29). It is important to 
highlight that CFS from MO15 corresponded to maximum inhibition radius (12,7 mm) 
against S. aureus, when compared to the inhibitions against the remaining indicator 
bacteria (Figure 28). 
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Figure 28 - Bioactivity results of cell-free supernatants (CFS) determined by agar-well diffusion assay (AWDA) 
against the Gram-positive and Gram-negative indicator bacteria (these results continue on the next figure). 
Each point represents the measurement mean of 3 biological replicas halos from the same experience. 
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Figure 29 – Continuation: bioactivity results of cell-free supernatants (CFS) determined by agar-well diffusion 
assay (AWDA) against the Gram-negative indicator bacteria. Each point represents the measurement mean of 
3 biological replicas halos from the same experience. 
 
Comparing the bioassay results obtained with colony and liquid cultures (Figure 30), 
it was notorious that, in the majority of the cases, the antimicrobials produced in solid 
medium were not detected in CFSs using the agar-well diffusion assay. The lack of 
activity can be due to the absence or insufficient production of the compounds in the 
conditions tested and these differences have also been noticed on previous studies 
(Compaoré et al., 2013; Phelan et al., 2013; Prieto et al., 2012). In order to improve or 
stimulate the antimicrobial production in liquid media, alternative and more specific media 
can be further tested. For instance, the media YEME and KM4 can be used in 
Streptomyces isolates (POR15(1), VT1, AR1 and M1) (Kieser et al., 2000). Nevertheless, 
when the production in liquid media is not successful, the extraction of antimicrobial 
compounds from solid media for additional characterization can be optimized (Völler et al., 
2012). Still, for some Bacillus spp. isolates (SL8, Sma1, MO15 and MO22), the spectrum 
of activity of the CFSs was even wider than that detected in the colony bioassay. 
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Based on these results, the isolates SL8, Sma1 and MO15 were selected for further 
characterization, since they were able to inhibit almost all the indicator strains tested. 
Even more importantly, their products were active against Gram-negative bacteria, which 
are normally more difficult to identify. All of these three isolates showed activity against 
bacteria with impact in food industry, such as L. monocytogenes and S. enteritidis. For 
instance, the food-spoiler L. monocytogenes is reported in several dairy products, meat 
products and sorts of seafood, being implicated in listeriosis cases in humans and other 
animals (Farbed and Peterkin, 1991; Rossmanith et al., 2006). Regarding Salmonella 
spp., they usually colonize all of the major livestock species (poultry, cattle and pigs), 
resulting in contaminated meat and other food products of animal origin. Thus, this 
bacterium is mostly associated with salmonellosis in humans, mainly due to the improper 
handling of animal-based food (Newell et al., 2010). On the other hand, Aeromonas 
hydrophila is a bacterium that can infect various hosts, including important fish species at 
a commercial level, such as eels. These infection diseases caused by A. hydrophila has 
been a major problem resulting in serious economic losses in aquaculture sector (Cao et 
al., 2011; Fang et al., 2004). The SL8, Sma1 and MO15 isolates also inhibit the growth of 
indicator bacteria with clinical relevance, such as enterococci, staphylococci and E. coli. 
Thus, the secondary metabolites of SL8, Sma1 and MO15 isolates can have potential as 
natural biopreservatives for control of potential pathogenic and spoilage microorganisms 
in food industry, in aquaculture sector and they can also be applied in clinical area due to 
their  notable  antimicrobials’  competence. 
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Figure 30 - Comparison of the results obtained using colony (C) and cell-free supernatants (L) bioassay. 
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POR15
(1) ± - - - - - ± - ± + - - ± - - - - - - - - - - - 
VT1 + + - - + + + + + + + + + - - - - - ± - - - + - 
VT4 - - - - ± - - - ± - - - ± - - - - - - - - - - - 
AR1 ± - - - + - + - + - ± - - - - - - - - - - - ± - 
AR9 - - - - ± - - - ± - - - ± - - - - - - - - - ± - 
LA1 - - - - ± - - - ± - - - ± - - - - - - - - - - - 
αA ± - - - ± - + - ± - ± - + - - - - - - - ± - ± - 
M1 ± - ± - ± - + - + + + - + - - - - - - - - - ± - 
NL9 ± - - - ± - + - ± - ± - - - - - - - ± - - - ± - 
NL11 - - - - - - - - ± - - - ± - - - - - ± - - - - - 
MO23 - - - - + - - - - - - - - - ± - ± - - - - - - - 
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αB - - - - + - + - + - - - - - ± - ± - + - - - ± - 
SL1 - - - - - - - - + + - - - - - - - - - - - - - - 
SL3 - + - - - - + - + + + - + + - - - - - - - - - - 
SL8 - + + + + + + + + + + + + + + + - + - - + + - + 
SL11 - - - - - - - - + - - - - - - - - - - - - - - - 
NL8 - - - - - - - - + - - - - - - - - - - - - - - - 
SMA1 + + + + + + + + + + - + + + + + - + ± - + + + + 
MO15 - + - + + + + + - + - + + + - + - + - - - + - + 
MO22 - + - + - - + + + + - - + + - - - - - - + + - - 
MO27 - - - - - - - - + - - - - - - - - - - - - - - - 
MO31 - + - - - - - - + + - - ± - - - - - - - - - - - 
Note: in this table, the incubation times were not considered. 
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2.3 Effect of temperature and proteolysis on the antibacterial activity of 
SL8, Sma1 and MO15 isolates 
The stability of antimicrobials produced by SL8, Sma1 and MO15 isolates to 
increasing temperature (Figure 31) and proteolytic activity (Figure 32) was tested. This 
was accomplished using the CFSs from these three isolates collected after 48 h of 
incubation. B. cereus and A. hydrophila were chosen as indicator strains, once they were 
the most affected Gram-positive and Gram-negative bacteria, respectively, by the SL8, 
Sma1 and MO15 CFSs. 
The thermal bioassay has been used to determine the nature of an antimicrobial, 
which, in turn, influences its possible applications. Relatively to bacteriocins, this bioassay 
has been used not only to prove its presence as antimicrobial, since they are 
characterized to be thermo-resistant, but also to determine, for instance, their possible 
applications as food preservatives, where they have to remain stable during processing 
operations (Ben Belgacem et al., 2012). To complement this information, the study of 
proteolysis effect on antimicrobial CFSs is also widely used. This leads to some 
information regarding the nature of the antimicrobials, more specifically if they have any 
peptidic moiety available to the enzymes’  action.  Thus,  several  studies  included  these  two  
assays, in order to characterize a new natural antimicrobial (Cladera-Olivera et al., 2004; 
Lisboa et al., 2006; Phelan et al., 2013; Prieto et al., 2012). 
 
 Effect of temperature 2.3.1
In a general perspective, the exposition of CFSs to increasing temperatures led to 
the decrease of activity (Figure 31). Relatively to B. cereus inhibition results (Figure 31A), 
it was found that the antimicrobials produced by SL8 and Sma1 had a similar behavior in 
this bioassay: approximately 50 % of their activity was lost after the incubation at 80 ºC, 
whereas some activity was still observed after the treatment at 100 °C. Regarding the 
CFS of MO15 strain, it was found that the antibacterial(s) inhibiting B. cereus were 
relatively stable to all temperatures tested. Overall, the untreated samples were less 
active against A. hydrophila than B. cereus. Thus, different antimicrobial(s) can be 
involved in the inhibitory effect observed for these two strains. For instance, some of 
compounds active against B. cereus can be inactive towards A. hydrophila, due to the 
outer membrane protective barrier. The results also showed that half of the CFS activity 
against A. hydrophila was lost after incubation at temperatures between 70 ºC and 80 ºC. 
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Nevertheless, Sma1 and SL8 retained a little of its activity after being exposed to 100 °C, 
whereas MO15 CFS was totally ineffective when treated at 90 °C. 
 
Figure 31 - Effect of temperature in the antimicrobial activity of SL8, Sma1 and MO15 cell-free supernatants 
(CFSs) against B. cereus (A) and A. hydrophila (B). Each point represents the measurement mean of 3 
biological replicas. 
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 Effect of proteolytic enzymes 2.3.2
All the four enzymes tested in the present work were proteolytic enzymes belonging 
to hydrolase class (Enzyme Commission - EC 3), subclass of peptide hydrolases (EC 
3.4). 
The antimicrobial activity of the CFSs from SL8 and Sma1 against B. cereus was 
slightly  reduced  with  the  treatment  with  α-chymotrypsin and trypsin (Figure 32). However, 
these enzymes had no evident impact in MO15 activity against the same indicator. 
Considering the results obtained for A. hydrophila inhibition with the same two proteases, 
it was found that they had no effect in the antibacterial activity of SL8 and Sma1 CFSs. 
However they affected the ability of MO15 compounds to control the growth of this Gram-
negative bacterium. Thus, it is expected that some of antimicrobials produced by MO15 
and targeting A. hydrophila possess a peptidic moiety. This moiety should contain at least 
one tyrosine (Tyr),  tryptophan  (Trp),  phenylalanine  (Phe)  or  leucine  (Leu)  residue,  since  α-
chymotrypsin cleaves the peptide bond after these hydrophobic amino acids. Additionally, 
they should also contain an arginine (Arg) and/or lysine (Lys) because trypsin cleaves 
exclusively the C-terminal of these positively charged residues (Olsen et al., 2004). 
The serine protease proteinase K cleaves preferentially peptide bonds adjacent to 
the carboxyl group of any aliphatic or aromatic amino acid residue. The inhibition halos of 
SL8 and MO15 did not suffer a noticeable reduction against the Gram-positive indicator, 
after exposition to this protease. However, in the same conditions, a slightly decrease of 
Sma1  CFS’s   activity   was   detected.   Against   the  Gram-negative indicator bacterium, the 
proteolytic activity of proteinase K had impact exclusively in the CFS of MO15. 
Pronase E treatment was responsible for the total loss of activity of the SL8 and 
MO15 CFSs against A. hydrophila. This protease also decreased appreciably the activity 
of SL8 CFS against B. cereus and the CFS from Sma1 against both of the indicator 
strains. On the contrary, the compounds produced by MO15 strain responsible for B. 
cereus inhibition were not affected by pronase E action (considering error bars 
overlapping from control and corresponding treated sample). 
Overall, the pronase E was the protease with more impact in the activity of the 
tested CFSs. In fact, pronase E activity is not stringent, since it is a mixture of at least 10 
proteases produced by Streptomyces griseus K-1 able to digest casein to the extent of 
>70% as mono-amino acids (Burrell, 1993). In fact, its preferential cleavage site is 
P6P5P4P3P2P1ÐP1’P2’P3’P4’,  where  P1  and  P1’  are  hydrophobic  amino  acids  (alanine  
(Ala), valine (Val), leucine (Leu), isoleucine (Ile), phenylalanine (Phy), tryptophan (Trp) 
and tyrosine (Tyr)). It is worth to mention that proteinase K and pronase E alone had 
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inhibitory activity against the Gram-positive B. cereus. Nevertheless, such effect was 
never superior to the untreated or treated CFSs (Figure 32). The other control constituted 
by the buffer alone had no effect in the indicator strains and therefore were not included in 
the results (Figure 32). 
 
 
Figure 32 - Effect of proteolytic enzymes on SL8, Sma1 and MO15 cell-free supernatant (CFS) antimicrobial 
activity against B. cereus (A) and A. hydrophila (B). Each point represents the measurement mean of 3 
biological replicas. 
 
A) B) 
0,0
1,0
2,0
3,0
4,0
5,0
6,0
7,0
8,0
9,0
Ra
di
us
 o
f i
nh
ib
iti
on
 (m
m
) 
SL8 untreated SL8 treated Enzyme
0,0
1,0
2,0
3,0
4,0
5,0
6,0
7,0
8,0
9,0
Ra
di
us
 o
f i
nh
ib
iti
on
 (m
m
) 
Sma1 untreated Sma1 treated Enzyme
0,0
1,0
2,0
3,0
4,0
5,0
6,0
7,0
8,0
9,0
Ra
di
us
 o
f i
nh
ib
iti
on
 (m
m
) 
MO15 untreated MO15 treated Enzyme
0,0
1,0
2,0
3,0
4,0
5,0
6,0
7,0
8,0
9,0
Ra
di
us
 o
f i
nh
ib
iti
on
 (m
m
) 
SL8 untreated SL8 treated Enzyme
0,0
1,0
2,0
3,0
4,0
5,0
6,0
7,0
8,0
9,0
Ra
di
us
 o
f i
nh
ib
iti
on
 (m
m
) 
Sma1 untreated Sma1 treated Enzyme
0,0
1,0
2,0
3,0
4,0
5,0
6,0
7,0
8,0
9,0
Ra
di
us
 o
f i
nh
ib
iti
on
 (m
m
) 
MO15 untreated MO15 treated Enzyme
Search for new lantibiotics 
 
 48 
These results point out that the antibacterial activity of SL8, Sma1 and MO15 
strains against B. cereus and A. hydrophyla should result from a mixture of compounds, 
including those containing peptidic moieties. In fact, the activity of SL8 and MO15 against 
A. hydrophyla seems to be exerted mainly by peptidic products or molecules with a 
peptide moiety. The same can be proposed for the effect of Sma1 on B. cereus. However, 
against this Gram-positive bacterium, the majority of antimicrobials produced by SL8 and 
MO15 should not have a proteinaceous nature. 
 Nevertheless, the absence of an effect in activity after the treatment with proteases 
does not always exclude the possibility of antimicrobials containing proteinaceous 
structure. For instance, it is known that some antimicrobials produced by Bacillus spp. are 
cyclic peptides containing unusual amino acids, conferring them more resistance to 
proteases (von Dohren, 1995; Lisboa et al., 2006). In the group of lantibiotics, their Lan 
and MeLan thioether bridges normally contribute to its lower sensitivity to proteolytic 
activity. For instance, it was shown that the removal   of   a   Lan   bridge   (ring   A   of   Lntα)  
resulted in thermal and proteolytic sensitivity of the lantibiotic Lacticin 3147 (Suda et al., 
2010).  The  native  Lacticin  3147   is  susceptible   to  proteinase  K  and  α-Chymotrypsin and 
stable when treated with peptidase, pepsin, trypsin and pronase E (1 mg/mL at 37 °C for 1 
to 3 h) (Gardiner et al., 2007; Suda et al., 2010). On the other hand, the lantibiotic 
subtilomycin  was  found  to  be  susceptible  to  pronase  E  and  insensitive  to  α-Chymotrypsin 
and proteinase K (1 mg/mL at 37 °C for 1 h) (Phelan et al., 2013). 
Moreover, in this study, the antimicrobials produced by SL8, Sma1 and MO15 in 
liquid cultures were tested using only one concentration of each protease. Then, it is still 
possible that all the proteases affect their antimicrobial activity, if used at a concentration 
superior to 5 mg/mL, as it was observed for some antimicrobials produced by B. 
amyloliquefaciens (Lisboa et al., 2006). 
2.4 Affiliation of SL8, Sma1 and MO15 isolates to the specie level 
The amplification and sequencing of 16S rRNA gene did not allow the specie 
discrimination of the isolates SL8, SMA1 and MO15. The comparison of their 16S rRNA 
sequences with those available in databases was performed using BLAST®. The results 
revealed their 99% identity with different Bacillus spp. isolates classified as B. 
amyloliquefaciens, B. subtilis, B. vallismortis and B. velezensis. 
Therefore, the sequence of the gyrA gene, encoding the subunit A of DNA gyrase 
was amplified and analyzed. The use of BLAST® tool revealed 99% of identity between 
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gyrA sequence of the three isolates and those of B. amyloliquefaciens and B. velezensis 
strains. However, it was found that B. velezensis is a later heterotypic synonym of B. 
amyloliquefaciens (Wang et al., 2008). Moreover, the phylogenetic analysis of gyrA 
nucleotide sequences suggested that SL8, Sma1 and MO15 isolates are B. 
amyloliquefaciens, more specifically belonging to the subspecie plantarum (Figure 33). 
 
 
Figure 33 – Phylogenetic tree based on the gyrA nucleotide sequences of several Bacillus spp. isolates. The 
type strains for the two subspecies of B. amyloliquefaciens are in bold. The B. cereus ATCC 14579 sequence 
was included as an outgroup representative. 
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2.5 Identification of clusters of lanthipeptides in B. amyloliquefaciens 
genomes by genome mining 
Currently, 13 B. amyloliquefaciens genome projects are finalized (data available at 
NCBI site on 20th of October, 2013). Therefore, the identification of gene clusters typically 
involved in the production of lanthipeptides was performed using the bioinformatics tool 
antiSMASH 2.0 in those 13 genomes. The antiSMASH 2.0 constitutes a platform for the 
genome mining of a vast diversity of secondary metabolites, including lanthipeptides 
(Medema et al., 2011). The results revealed the presence of gene clusters encoding the 
biosynthesis of different families of natural compounds, most of them with antimicrobial 
activity, in all the 13 genomes. These included NRPS, PKS and terpenes. The 
biosynthetic clusters characteristic of lanthipeptides were also detected, however in only 3 
of the analyzed strains: B. amyloliquefaciens Y2, B. amyloliquefaciens YAU B9601-Y2 
and B. amyloliquefaciens IT-45. These three clusters will be discussed in more detail in 
the following sections. 
 Bacillus amyloliquefaciens Y2 and YAU B9601-Y2 2.5.1
The strains B. amyloliquefaciens subsp. plantarum Y2 (accession number 
NC_017912) and YAU B9601-Y2 (accession number NC_017061) were both isolated 
from wheat rhizosphere and are considered plant-growth promoters (Hao et al., 2012). 
Using the platform antiSMASH 2.0, a typical cluster for the production of lanthipeptides 
was identified in these two strains (Figure 34). The BLASTX analysis of the lanM gene of 
the two clusters revealed a 100% identity with the MrsM enzyme, involved in the 
production of mersacidin. This lantibiotic is a class II lanthipeptide composed by 20 amino 
acids, which is active against MRSA (Bierbaum et al., 1995; Herzner et al., 2011; Motta et 
al., 2007). In fact, the two clusters found by antiSMASH were identical to the full 
mersacidin cluster. However, two genes were not detected by this analysis: i) the 
mersacidin structural gene (mrsA), in the cluster of YAU B9601-Y2 strain and ii) the gene 
encoding the MrsD flavoprotein, in the cluster of Y2 strain. Nevertheless, using the 
graphical analysis tool ORF finder, it was possible to identify these two genes in the 
respective gene clusters (arrows with dashed lines; Figure 34). Thus, B. 
amyloliquefaciens subsp. plantarum YAU B9601-Y2 and Y2 strains have the complete 
mersacidin biosynthetic gene cluster in their chromosomes. 
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Figure 34 – Representation of mersacidin biosynthetic cluster already well-characterized (A) and the 
mersacidin clusters detected in Bacillus amyloliquefaciens subsp. plantarum Y2 (B) and YAU B9601-Y2 (C) 
by antiSMASH 2.0 analysis. The genes not detected by this platform are represented with dashed lines. 
 
 Bacillus amyloliquefaciens IT-45 2.5.2
The antiSMASH analysis of this bacterial genome (accession number NC_020272) 
identified  a   lanthipeptide’s  gene  cluster  containing  2   lanM (class II lanthipeptides) and 2 
putative lanA genes. This cluster was designated as bam and its partial representation is 
present on Figure 35. 
 
 
Figure 35 – Partial   representation  of   lanthipeptide’s  cluster  detected   in   the  Bacillus amyloliquefaciens IT-45 
chromosome by antiSMASH 2.0 analysis. A1 is respectable to a possible lantibiotic structural gene 
(KSO_013315), M1 and M2 correspond   to   two   different   modification   enzymes’   genes,   T to the gene that 
codifies the LanT transporter and FEG to putative immunity genes. #1, #2 and #3 correspond to genes 
associated with two-component regulatory components. The dashed arrows (A2, A3 and A4) correspond to 
putative lanA genes recognized after ORF finder search analysis. 
 
Table 1 – Sequence of the precursor peptides encoded by the structural genes detected with antiSMASH 2.0 
of the B. amyloliquefaciens IT-45 genome. p represents the cleavage site proposed in the antiSMASH 
analysis. The underlined amino acid residues correspond to the most probable cleavage-site of the leader 
peptide, according to this study. The residues essential for the biosynthesis of lanthipeptides are shown in 
bold (Ser, Thr and Cys). 
Gene Locus Leader p core peptide sequence 
KSO_013260 MINEQRARSYIHWSYAAHEVLGG p QHGDYSVMMQKPFLRCQNDDILPAVF 
KSO_013315 MNEKMYRFAGDLREELEEISLS p EFSGGGGAEQRGISQGNDGKLCTLTWECGLCPTHTCWC 
 
Regarding the 2 structural genes founded by antiSMASH 2.0 (Table 1), the one with 
the gene locus number KSO_013260 did not show potential to constitute a mature 
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lanthipeptide, since it can possibly form only one thioether bridge (its core peptide only 
contains 1 Ser and 1 Cys residues), which is uncommon among this class of compounds. 
The other structural gene (KSO_013315) codifies for a precursor peptide constituted by a 
core peptide possessing several Ser, Thr and Cys residues. Thus, this is more likely to be 
a lanA gene. However, the leader peptide removal should occur a few amino acids 
downstream (GA motif; Table 1) to that proposed by the antiSMASH. This is also 
supported by the fact that, in class II lanthipeptides, the preferential cleavage site is the 
“double  Gly  motif”   (GG,  GA  or  GS)   (Caetano, 2011; Chatterjee et al., 2005b). Then, the 
mature peptide (core peptide after modification process) should be composed by 4 MeLan 
(thioether bond between Dhb and Cys residues) and 1 Lan (thioether bond between Dha 
and Cys residues). Thus, it was considered that only KSO_013315 encodes a real lanA 
structural gene. 
However, 2 lanM genes are present in this cluster, making it expectable to find at 
least other lanA gene. Since these clusters usually comprise genes close to each other in 
Bacillus genus, a search for the presence of potential lanA ORFs between lanM1 and 
lanT1 was performed using ORF finder. Among the 6 ORFs identified, 3 of them seemed 
promisor  ORFs   to   constitute   lanthipeptide’s precursors (Figure 35). The analysis of the 
encoded sequence demonstrated that 2 of them originate exactly the same peptides 
containing 58 amino acids (A2 and A3 in Table 2). Moreover, these two peptides showed 
similarity with an uncharacterized peptide of B. cereus and with class II lantibiotics already 
characterized, such as the E peptide of lichenicidin (BliE) and haloduracin (HalE) (Figure 
36). Thus, A2 and A3 genes have a high probability to constitute the precursor peptides of 
lantibiotics, since the majority of class II lanthipeptides known possess antibacterial 
activity. 
The last gene (A4) codifies a peptide with 52 amino acids (Table 2) that showed no 
homology with any lantibiotic. However, its sequence has some characteristics of this 
class of compounds, such as i) the double Gly-motif, ii) the presence of Cys residues only 
after the Gly-motif (core peptide) and iii) several Ser and Thr residues close to Cys (Table 
2). Therefore, according to this analysis, there are 3 possible lanthipeptides with 
probability of being produced by IT-45 strain. 
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Table 2 – Sequence of the potential precursor peptides detected in this study in the B. amyloliquefaciens IT-
45 genome. p represents the most probable cleavage site and the residues essential for the biosynthesis of 
lanthipeptides are shown in bold (Ser, Thr and Cys). 
Gene Leader p core peptide sequence 
A2 MKKDFQALTPMTEEELKNLAGGS p DATPMTVTPTTITIPISLAGCPTTKCASIVSPCND 
A3 MKKDFQALTP MTEEELKNLAGGS p DATPMTVTPTTITIPISLAGCPTTKCASIVSPCND 
A4 MKENFSALYETSEQELRELIGG p QNSVSITTIPITNHVCPTITVGCACPQRQV 
 
Identities: 63% 
 
Identities: 57% 
 
Identities: 46% 
 
Figure 36 - BLASTp alignment results between the peptide sequence A2/A3 and: 1) hypothetical protein 
[Bacillus cereus], accession number WP_016132309; HalE: lantibiotic haloduracin [Bacillus halodurans C-125], 
accession number NP_241319 and BliE: lantibiotic lichenicidin [Bacillus licheniformis DSM 13 = ATCC 14580] 
accession number YP_006715399. The matching residues are represented by grey color. 
 
Considering the remaining genes of the cluster, the lanT (Figure 35) encodes a 
classical class II LanT, constituted by an ATP-binding domain and a C-terminal protease 
domain (through a BLASTp search). The gene KSO_013345 must codify for a LanF 
protein (F, Figure 35), since it possesses an ATP-binding motif (Draper et al., 2008). 
Moreover, by performing a multiple sequence alignment with LanF from other lantibiotic 
gene clusters, the conserved motifs characteristic of this nucleotide-binding subunit, 
including Walker A, Walker B, E-loop, Signature and H-loop (Okuda and Sonomoto, 2011) 
were identified (Figure 37). It is important to refer that LanF proteins contain the E-loop 
motif instead of the usual Q-loop of ABC transporters. The E-loop is considered to be 
involved in the conformational change of the transmembrane subunits E (lanE) and G 
(lanG), being a key factor on the lantibiotic-transport mechanisms (Okuda et al., 2010; 
Okuda and Sonomoto, 2011). 
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Figure 37 – Multiple sequence alignment of LanF protein identified in IT-45 genome and other LanF proteins 
involved in the self-protection of already characterized lantibiotics. Residues involved in conserved motifs 
(Walker A, E-loop, Signature, Walker B and H-loop) are shown. Accession numbers: NukF, NP_940775; LctF, 
AAC72253; MrsF, CAB60255; NisT, CAA82547; MutF, AAF99691. 
 
The lanE and lanG genes are usually found next to lanF. Then, the gene with the 
accession number KSO_013340 (E/G, Figure 35) must probably codifies for LanE/G 
protein. The analysis of the correspoding protein using the TMHMM Server v. 2.0 showed 
that it is composed by 6 transmembrane domains, which are a key characteristic of LanE 
and LanG proteins (Saris et al., 1996). Thus, it was considered that this gene, together 
with F gene, constitute the self-protection system of the strain to the lantibiotics produced 
by the biosynthetic cluster. The remaining genes KSO_013320, KSO_013325, 
KSO_013330 and KSO_013335 (#1, #2, #3 and #4, respectively, in Figure 35) showed 
homology with LanR and LanK proteins, most probably involved in transcriptional 
regulation of the remaining genes. 
2.6  Screening of mersacidin genetic determinants and production in 
SL8, Sma1 and MO15 
As abovementioned, two different clusters typical of lanthipeptides production were 
identified in B. amyloliquefaciens chromosomes by genome mining analysis: the 
mersacidin (mrs) cluster and an uncharacterized cluster (bam). Thus, the presence of 
some mersacidin genetic determinants in the SL8, Sma1 and MO15 isolates was 
investigated. In this context, the amplification of a fragment containing the mersacidin 
structural gene (mrsA), the regulator gene (mrsR1) and the flavoprotein gene (msrD) from 
SMA1, SL8 and MO15 total DNA was successful (amplicon of 1600 bp). However, the 
gene codifying the mersacidin modification enzyme MrsM (amplicon with about 3000 bp) 
was only identified in SL8 and Sma1 isolates. Consequently, the amplification of a lanM 
gene from MO15 strain was attempted using degenerated primers and Sma1 as a positive 
control. Nevertheless, no amplicons were obtained, indicating the absence of these type 
of genes in the MO15 isolate. Thus, it will be possible that SL8 and Sma1 isolates 
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possesses the complete mrs gene cluster, whereas MO15 is expected to have the same 
cluster, but incomplete. 
Due to the detection of mrs genetic determinants in the SL8, Sma1 and MO15, their 
ability to produce mersacidin was evaluated. This was performed in order to understand if 
mersacidin was contributing for their spectrum of activity, detected in this study. To 
achieve this, the CFSs were obtained from the same conditions as the ones used for 
stability testing to temperature and proteolytic activity. After extraction and evaporation of 
the supernatants, the crude extracts were analyzed using MALDI-TOF/MS. The expected 
mersacidin molecular masses [1826 Da: mersacidin + H; 1848 Da: mersacidin + Na and 
1864 Da: mersacidin + K] (Herzner et al., 2011) were not detected in any of the extracts 
(Figure 38). These results were expected at least for MO15 B. amyloliquefaciens subsp. 
plantarum strain, once the amplification of mrsM gene was not successful. In this case, 
the modification process on the mersacidin precursor peptide cannot occur. However, the 
SL8 and Sma1 isolates possess this gene. The absence of production by these two 
isolates can have multiple explanations, including the use of inappropriate media for 
mersacidin production or the absence of other genes in the cluster not evaluated in this 
study (as mrsT). In order to confirm these two possibilities, a PCR screening for the 
remaining genes should be achieved and these bacteria should be cultivated in media 
already described for mersacidin production (Bierbaum et al., 1995; Herzner et al., 2011). 
Since the lantibiotic mersacidin was not detected in any studied CFSs, the 
bioactivity of bacterial isolates SL8, Sma1 and MO15 B. amyloliquefaciens subsp. 
plantarum was probably conferred by other natural products’ classes, which were 
common to all 13 B. amyloliquefaciens genomes analyzed, such as NRPS, PKS and 
terpenes. 
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Figure 38 – MALDI-TOF mass spectra of CFSs from MO15 (A), Sma1 (B) and SL8 (C) after butanol extraction. 
The typical mersacidin-related mass signals [1826 Da: mersacidin + H, 1848 Da: mersacidin + Na and 1864 
Da: mersacidin + K] were not detected. 
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The sampling sites selected for the present work were source of microorganisms 
with remarkable antimicrobial activities. 
Through colony bioassay we found that a large number of the bacterial isolates 
collected produced potent antimicrobial compounds capable of inhibiting a wide range of 
Gram-positive and Gram-negative bacteria, including pathogens such as Listeria 
monocytogenes and Escherichia coli. A comparison of the results obtained in solid and in 
liquid medium led us to conclude that possibly more than one antimicrobial compound 
was produced by the same isolate, since a different inhibitory spectrum was obtained, 
depending on the culture conditions used. 
Three bacteria, SL8, Sma1 and MO15, identified as B. amyloliquefaciens, were 
selected to test the antimicrobial compounds’ stability when the culture supernatant was 
exposed to different temperatures and proteases. Results showed that these 
antimicrobials were thermo-sensible, with the exception of those produced by MO15 CFS, 
that was able to inhibited B. cereus. Nevertheless, the antimicrobials produced by SL8 
and Sma1, effective against B. cereus, retained nearly 50% of their initial activity when 
placed at 100 °C for 30 min. The effect of proteases suggested that these antibacterials 
should be mostly of non-peptidic nature. Nevertheless, when these compounds were 
treated with Pronase E, bioactivity of SL8 and MO15 CFSs against A. hydrophila was 
completely abolished. 
A genome mining analysis using the platform antiSMASH allowed the identification 
of gene clusters encoding secondary metabolites with antibacterial activity in all the 
sequenced and assembled B. amyloliquefaciens genomes. However, it was found that the 
interpretation of the results retrieved by antiSMASH requires a critical judgment of the 
user. For instance, herein new structural genes that probably encode lanthipeptides were 
identified in some of the genomes analyzed that were not detected by the antiSMASH 2.0 
algorithm. These genes have not been characterized yet and finding it was an important 
achievement of the present work. Moreover, the biosynthetic cluster of the lantibiotic 
mersacidin was found in two of the deposited genomes. But, despite that, this lantibiotic 
was not detected in any of the supernatants analyzed by MALDI-TOF/MS. Nevertheless, 
SL8 and Sma1 are B. amyloliquefaciens strains that might have potential to produce this 
lantibiotic because they possess both mrsA, mrsD and mrsM genes. 
The results herein obtained showed that the B. amyloliquefaciens SL8, Sma1 and 
MO15 isolates produce natural compounds that inhibit both pathogenic and food spoilage 
microorganisms, with possible applications in health, food, agriculture and aquaculture 
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areas. Nevertheless, further studies are still required. Thus, further investigations will be 
performed and include: 
i)  Complete the stability tests using CFSs; these will include the evaluation of 
the impact of pH as well as the impact of other enzymes (such as lipases 
and amylases) on the antibacterial activity of the compounds produced; 
ii) Amplification of the complete cluster involved in the biosynthesis of the 
lantibiotic mersacidin; 
iii) Evaluation of mersacidin production using different culture conditions and 
other peptide extraction procedures; 
Moreover, PCR screening of clusters possibly associated with lantibiotic production, 
and targeting lanB/lanC (class I) and lanM genes (class II), will be performed on all the 
remaining isolates possessing antibacterial activity. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4 Experimental procedures 
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4.1 Bacterial isolates 
The bacterial strains used in this study were isolated from soil of an abandoned 
uranium mine, soil from caves and roots of Eryngium sp. collected in an abandoned iron 
mine (Table 3). The soil samples from caves were collected in Algarve region (Portimão, 
Vale Telhado and Algar Romão) by Doctor Sofia Reboleira (Department of Biology and 
CESAM, University of Aveiro). The MO bacterial isolates (Table 3) were provided by 
Doctor Catarina Marques (Department of Biology and CESAM, University of Aveiro) and 
Professor Doctor Ruth Pereira (Department of Biology, University of Porto and CESAM, 
University of Aveiro). 
All isolates were grown at 26 °C and maintained in trypic soy agar plates (TSA; 
Merck) at 4 °C. 
 
Table 3 –Local of isolation and designation of the bacterial isolates used in the present study. 
Product Sampling area Designation of isolates 
Soil Abandoned uranium mine, Cunha Baixa, Portugal 
Close to the 
lagoon SL, LA, NL 
“Lamas” M, SMA, NM 
Soil Caves, Algarve, Portugal 
Algar Romão AR 
Portimão POR 
Vale Telhado VT 
Root Plant Eryngium sp. from an abandoned iron mine, Ait 
Amar, Morocco MO, α 
4.2 Detection of bacteria with antibacterial activity 
In order to test the inhibitory bioactivity of the bacterial isolates, three different agar-
based tests (deferred-antagonism testing) were performed: colony bioassay, overlay 
bioassay and “sandwich” bioassay. For each of these assays, several indicator strains 
were used, including Gram-positive and Gram-negative bacteria (Table 4). The indicator 
strains were always grown on 20 mL of trypic soy broth (TSB; Merck) using 50 mL 
falcons, at the appropriate temperature (Table 4) with aeration (180 rpm), overnight. 
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Table 4 - Indicator strains used in this study and respective incubation temperatures. 
Indicator strains Origin Growth temperature 
Gram positive   
Bacillus cereus Av2 Aveiro Lagoon1 26 ºC 
Enterococcus faecalis ATCC 29212  
37 ºC 
Enterococcus faecium 547261 Clinical isolate 
Haemophilus influenzae 121642 Clinical isolate 
Listeria monocytogenes 71 Clinical isolate 
Micrococcus luteus ATCC 9341   
Staphylococcus aureus ATCC 29213  
Gram negative   
Aeromonas hydrophila ATCC 7966  26 ºC 
Escherichia coli ATCC 35218  
37ºC 
Klebsiella pneumoniae 100603 Clinical isolate 
Pseudomonas aeruginosa PAO1  
Salmonella enteretidis ATCC 13076  
1(Cruz et al., 2007) 
 
 Colony bioassay 4.2.1
In this assay, 45 mL of melted TSA were inoculated with the respective indicator 
strain at a final concentration of 0.02 (in terms of OD600) and poured on a petri dish. After 
solidification, a colony of each bacterial isolate to be tested was streaked on the top of the 
prepared plate. The plates were incubated at 26 °C for the desired time (24h, 48h, 72h 
and 7 days), followed by the evaluation of inhibition areas. 
 Overlay bioassay 4.2.2
This assay was performed to assess the antibacterial activity of isolates that are not 
able to grow at 37 ºC against the indicator strains that grow at this temperature (Table 4). 
Thus, 45 mL of TSA was used to prepare agar plates and one colony of each strain to be 
tested for antibacterial activity was streaked on it. After incubation at 26 °C, for the desired 
time, the plates were overlaid with 35 mL of TSA-soft agar containing the indicator strain 
at a final OD600 of 0.02. The presence of inhibition areas was evaluated after overnight 
growth at 37 °C. 
 
TSA-soft agar: TSB (Merck) medium containing 0.75% (w/v) of agar. 
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 Sandwich bioassay 4.2.3
This assay was performed to assess the antibacterial activity of all the isolates that 
were not tested by overlay bioassay against the indicator strains with optimal growth 
temperature of 37 ºC or 26 ºC (Table 4). Thus, the plates containing the colonies to be 
tested were prepared and incubated for the desired period as abovementioned (section 
4.2.2). After incubation, the agar of these plates was cut with a sterile bistoury and 
transferred to the top of TSA-soft agar plates containing the indicator strain. These plates 
were prepared as described in section 4.2.2. The inhibition areas were evaluated after 
incubation at 26 ºC or 37 ºC, according to the indicator strain tested (Table 4). 
4.3 Evaluation of antibacterial production in liquid cultures 
The production of antibacterial compounds in liquid cultures was also tested for 
isolates able to inhibit at least one indicator strain. To achieve this, each isolate was 
inoculated in 3 mL of TSB (tryptic soy broth; Merck) in a 14 mL tube and grown overnight 
at 26 °C with aeration (180 rpm). Subsequently, 1/100 volume of this culture was added to 
20 mL of fresh TSB in a 100 mL erlenmeyer. The culture was incubated at 26 ºC at 180 
rpm for 1 week. Along this period, 2 mL of culture were collected in each sampling time 
point (24 h, 48 h, 72 h and 1 week) in order to assess their antagonistic activity. 
Each samples was centrifuged at 16,100 x g for 10 min and the supernatant 
transferred to a clean microcentrifuge tube. Subsequently, each supernatant was filtered 
using a 0.45 µm cellulose acetate filter (WhatmanTM) to obtain cell-free supernatants 
(CFS). To assess the antibacterial activity of CFS, TSA plates containing the indicator 
strains were prepared as described in section 4.2. After solidification, wells with 7 mm 
diameter were poured off the agar and filled with 50 µL of each CFS to be tested. Finally, 
the plates were incubated overnight at the appropriate temperature for the indicator 
strains (Table 4) and the inhibition areas were measured. 
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4.4 Sensitivity of antibacterial compounds to enzymes and heat 
The sensitivity of antibacterial compounds to enzymes and heat was determined for 
the isolates that showed a broader spectrum of activity (SL8, Sma1 and MO15). To 
achieve this, CFS of each strain were prepared after 48 h of growth in the conditions 
described in section 4.3. 
 Effect of temperature 4.4.1
The sensitivity to temperature was evaluated by exposing 100 µL of each CFS 
during 30 min to the following temperatures: 40 °C, 50 °C, 60 °C, 70 °C, 80 °C, 90 °C and 
100 °C. Subsequently, 50 µL of all the treated and untreated CFS were applied to the 
bioassay agar plates (section 4.4.3). 
 Effect of proteolytic activity 4.4.2
The sensitivity of the same compounds to four different enzymes was also tested: 
Proteinase K (Roche Applied Science, REF: 03115879001); Trypsin from bovine 
pancreas (Sigma-Aldrich, T1426); α-Chymotrypsin (Sigma-Aldrich, C4129) and Protease 
from Streptomyces griseus (also known as Pronase E) (Sigma-Aldrich, P8811). The 
enzymes α-Chymotrypsin and Trypsin were dissolved in Tris-HCl 50 mM buffer (pH 7.5). 
The Proteinase K and Pronase E were dissolved in Tris-HCl 100 mM buffer (pH 7.5). All 
were prepared at a concentration of 10 mg/mL. The assay involved the incubation of the 
CFS with the corresponding enzyme using a 1:1 proportion in a 100 µL reaction for 2 
hours at 37 ºC. Afterwards, 50 µL of treated and untreated CFS were applied to the 
bioassay agar plates (section 4.4.3). 
 Preparation of bioassay agar plates 4.4.3
The sensitivity of antibacterial compounds to heat and enzymes was tested using 
Bacillus cereus Av2 and Aeromonas hydrophila ATCC 7966 as indicator strains. Thus, 
bioassay TSA plates (75 mL) containing each of these strains were prepared as described 
in section 4.2.1 and wells with 7 mm diameter were poured off the agar. Afterwards, the 
wells were filled with treated and untreated CFS as well as their respective controls. The 
plates were incubated at 26 ºC, overnight and the inhibition areas were analyzed. 
 
Experimental Procedures 
 67 
4.5 Identification of bacterial isolates 
 Analysis of 16S rRNA gene 4.5.1
The bacterial isolates with the ability to inhibit at least one of the indicator strains 
tested were identified by the analysis of the 16S rRNA gene. This gene was amplified 
using the RD1 (5’-AAGGAGGTGATCCAGCC-3’) and FD1 (5’-
AGAGTTTGATCCTGGCTCAG-3’) primers described by Edwards et al. (1989). Each 
reaction was performed at a final volume of 25 µL containing the reagents described on 
Table 5. The amplification parameters were as follows: one step of denaturation at 95 °C 
for 2 min followed by 30 cycles of denaturation at 95 °C for 30 sec, primer annealing at 56 
°C for 30 sec and extension at 72 °C for 2 min. A final extension step at 72 °C for 10 min 
was included. The reaction product was stored at -20 °C until further use or immediately 
run in an electrophoresis gel (see appendix 6.1). When necessary, the PCR product was 
purified from agarose gel (appendix 6.2). The sequence of the amplicon (approximately 
1600 bp) was submitted to sequencing reaction (STABVIDA-Portugal). The genus of each 
isolate was determined using the RDP Classifier tool (Wang et al., 2007). 
 
Table 5 – Components used for the amplification of 16S rRNA. 
Component of the reaction Volume 
MgCl2 (25 mM) 3 µL 
5x GoTaq polymerase buffer 5 µL 
dNTP Mix (10 mM each; NZYTech) 0.5 µL 
Forward primer (10 mM) 0.75 µL 
Reverse primer (10 mM) 0.75 µL 
DMSO 1.25 µL 
GoTaq polymerase (5 U/ µL; Promega) 0.125 µL 
DNA Template * ~ 1 µL 
Sterile, distilled water Until 25 µL 
* The DNA template was either 1 µL of a colony suspension (prepared in 100 µL of distilled water and 
boiled during 5 min) or 1 µL of genomic DNA (appendix 6.3). 
 
 Analysis of gyrA gene 4.5.2
The analysis of 16S rRNA full sequence did not allow the identification to the level 
specie of the Bacillus sp. isolates SL8, SMA1 and MO15. In this situation, the sequence 
was extremely highly conserved among different species of the same genera, limiting the 
power of discrimination (Miranda et al. 2013). Thus, the sequence of the gyrA gene 
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(referred to the subunit A of DNA gyrase) was also analyzed for these isolates. Its 
amplification was performed in a final volume of 25 µL as described in Table 5, using the 
primers gyrA_Bacilus_Fw (5’-CAGTCAGGAAATGCGTACGTCCTT-3’) and 
gyrA_Bacillus_Rv (5’-CAAGGTAATGCTCCAGGCATTGCT-3’) described by Koeppel et 
al. (2008). The amplification parameters were as follows: one step of denaturation at 95 
°C for 2 min followed by 30 cycles of denaturation at 95 °C for 30 sec, primer annealing at 
55 °C for 30 sec and extension at 72 °C for 1 min. A final extension step at 72 °C for 10 
min was included. The reaction product was stored at -20 °C until further use or 
immediately run in an electrophoresis gel (see appendix 6.1). The amplicon with expected 
size (approximately 1025 bp) was then submitted to nucleotide sequencing analysis 
(STABVIDA-Portugal). The sequences obtained were compared with those accessible in 
databases using the BLASTn web-based tool. Also, a neighbor joining (NJ) phylogenetic 
tree based on gyrA nucleotide sequences of several Bacillus species was constructed 
with the MEGA 5.1 software (Tamura et al., 2011) using the Neighbor-joining statistical 
method and 1000 bootstrap replications. 
4.6 Molecular genotyping of isolates with the same spectrum of activity 
The phylogenetic relationship of bacterial strains was investigated by rep-PCR 
fingerprinting, using BOX and ERIC-PCR (Rademaker and De Bruijn, 1997). Thus, each 
amplification reaction was performed in a final volume of 12.5 µL containing the reagents 
at the same final concentration as described in Table 5. For BOX-PCR, the BOXA1R (5’-
CTACGGCAAGGCGACGCTGACG-3’) primer was used as forward and reverse primer. In 
the ERIC-PCR reactions the primers Eric1 (5’-ATGTAAGCTCCTGGGGATTCAC-3’) Eric2 
(5’-AAGTAAGTGACTGGGGTGAGCG-3’) were used. The amplification parameters were 
as follows: one step of denaturation at 95 °C for 7 min followed by 35 cycles of 
denaturation at 94 °C for 30 1 min, primer annealing at 53 °C for 1 min and extension at 
65 °C for 8 min. A final extension step at 65 °C for 16 min was included. The products of 
amplification were submitted to electrophoresis as described in the appendix 6.1. The 
pattern of amplification was analyzed and isolates differing at least in one band were 
considered different strains. 
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4.7 Genome mining analysis 
The search for biosynthetic clusters (encoding secondary metabolites) on 
sequenced genomes was performed through an in silico analysis. For this purpose, the 
antiSMASH 2.0 platform was used (Medema et al., 2011). The accession numbers of all 
B. amyloliquefaciens genomes completely assembled presented on Genome Projects 
Report at NCBI (Table 6) were introduced to submit the analysis. This procedure was 
done aiming the potential of SL8, Sma1 and MO15 B. amyloliquefaciens isolates as 
producers of antibacterial secondary products, highlighting the lanthipeptides group. 
When necessary, the bioinformatic tool Open Reading Frame Finder (ORF Finder) 
was used as a complementary methodology, leading to the discovery of omitted genes on 
antiSMASH results. 
 
Table 6 – List of B. amyloliquefaciens genomes completely assembled used to perform the searching for 
secondary products biosynthetic clusters through an antiSMASH search. 
Accession number Microorganism affiliation 
NC_009725 Bacillus amyloliquefaciens FZB42 
NC_017061 Bacillus amyloliquefaciens subsp. plantarum YAU B9601-Y2 
NC_022081 Bacillus amyloliquefaciens subsp. plantarum UCMB5113 
NC_014551 Bacillus amyloliquefaciens DSM 7 
NC_020272 Bacillus amyloliquefaciens IT-45 
NC_017190 Bacillus amyloliquefaciens LL3 
NC_017188 Bacillus amyloliquefaciens TA208 
NC_017191 Bacillus amyloliquefaciens XH7 
NC_017912 Bacillus amyloliquefaciens Y2 
NC_019842 Bacillus amyloliquefaciens subsp. plantarum AS43.3 
NC_016784 Bacillus amyloliquefaciens subsp. plantarum CAU B946 
HG328253 Bacillus amyloliquefaciens subsp. plantarum UCMB5033 
NC_020410 Bacillus amyloliquefaciens subsp. plantarum UCMB5036 
 
The identification of each gene function was conducted by searching homologies 
with other protein sequences on Protein Basic Local Alignment Search Tool (BLASTp) 
NCBI’s database. The prediction of transmembrane helices domains in certain proteins 
was accomplished by using the TMHMM Server v. 2.0 (Krogh et al., 2001). 
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4.8 Detection of genetic determinants involved in the biosynthesis of 
mersacidin 
The genome mining analysis of B. amyloliquefaciens genomes revealed the 
presence of two gene clusters encoding the biosynthesis of class 2 lanthipeptides, 
including mersacidin. Thus, the presence of some of the mersacidin genetic determinants 
was investigated in the SL8, SMA1 and MO15 isolates by PCR. Each reaction was 
performed in a final volume of 25 μL as described in Table 5, using genomic DNA as DNA 
template. In order to amplify the gene encoding the mersacidin modifying enzyme (mrsM), 
the primers comp_MrsM_fw (5’-ATCAGGATCCATGCATACAAAATTCAAAC-3’) and 
comp_MrsM_rv (5’-TAGATCTCGAGTTACAATTTTAGTTCTAAAG-3’) were used. The 
genes encoding the transcriptional regulator (mrsR1), the flavoprotein (mrsD) and the 
mersacidin structural gene (mrsA) were amplified with the mrsA_fw (5’-
ATATACATATGAGTCAAGAAGCTATC-3’) and comp_mrsD_fw (5’-
ATCAGGATCCATGAGTATTTCAATATTAAAAG-3’) primers. The amplification 
parameters included one step of denaturation at 95 °C for 5 min followed by 30 cycles of 
denaturation at 95 °C for 30 sec, primer annealing at 53 °C (mrsM) or 50 ºC (mrsR1, mrsD 
and mrsA) for 30 sec and extension at 72 °C for 4 min. A final extension step at 72 °C for 
10 min was included. All the samples were submitted to electrophoresis as described in 
the appendix 6.1 in order to identify the presence of the expected amplicons (3000 bp for 
mrsM and 1600 bp for mrsR1, mrsD and mrsA). 
  Screening of lanM genes using PCR 4.8.1
The genome mining analysis revealed that B. amyloliquefaciens strains could 
encode other class II lanthipeptides in their genome, apart from mersacidin. Thus, the 
presence of genes encoding the modifying enzymes characteristic of class II 
lanthipeptides (LanM) was evaluated by PCR using degenerated primers designed in this 
study. 
 Amplification of lanM genes 4.8.2
The amplification of lanM genes was performed using the primers LanM_TC_fw (5’-
ATHYTIGARYTIAAYGTIGC-3’) and LanM_TC_rv (5’-ARISWICKIGGYTTRTAIAC-3’). 
Each reaction was performed in a final volume of 25 µL as described in Table 5, except 
that the final concentration of primers used was 3 pmol/µL. The amplification parameters 
were as follows: one step of denaturation at 95 °C for 5 min followed by 30 cycles of 
denaturation at 95 °C for 30 sec, primer annealing at 46 °C for 30 sec and extension at 72 
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°C for 45 sec. A final extension step at 72 °C for 10 min was included. The PCR was 
performed for B. amyloliquefaciens SL8, SMA1 and MO15 strains and Bacillus 
licheniformis I89 was included in all the reactions as positive control (Caetano et al., 2011; 
Mendo et al., 2004). All the amplicons possessing the expected molecular weight (300-
400 bp) were purified with the NZYtech PCR Purification kit, according to manufacturer’s 
instructions (see appendix 6.3). 
 Cloning of lanM genes 4.8.3
Class II lanthipeptides include the gene clusters of two peptide lantibiotics. Thus, it 
is possible that the same bacteria possess two distinct lanM genes. Therefore, all the 
amplicons were cloned into a vector, prior to sequencing reaction. 
Thus, after purification, the amplification products of each strain were ligated to the 
pCR2.1 plasmid from the TA Cloning Kit (Invitrogen), independently. Each reaction was 
performed in a final volume of 20 µL, containing approximately 50 ng of purified PCR 
product, 50 ng of pCR2.1 plasmid, 1X T4 DNA ligase ligation buffer and 4 U of T4 DNA 
ligase (Fermentas). The reaction was incubated at 22 °C for 30 min and 5 µL was used to 
transform chemically competent E. coli DH5α cells. Briefly, the ligation:cells mixture was 
placed on ice for 15 min and transferred to 42 °C for 45 sec. Immediately after, the 
microcentrifuge tube was placed on ice for 2 min and 950 mL of LB medium (Liofilchem) 
was added. The cells were grown for 1 hour at 37 °C with aeration (180 rpm). 
Subsequently, the culture was centrifuged at 2,300 x g for 1 min to collect cells. The 
majority of the supernatant was discharged and the pellet was resuspended in 
approximately 50 µL of the remaining supernatant. Finally, cells were spread on LB-agar 
(Nzytech) plates containing 50 μg/mL of kanamycin and 20 μg/mL of X-Gal. The positive 
clones were selected after overnight growth at 37 °C based on blue-white selection. 
 
X-Gal stock solution: dissolve 20 mg of X-Gal (Fermentas) in 1 mL of dimethylformamide. Protect the 
solution from the light covering the tube with aluminium foil and store at -20 °C. 
 
Luria-Bertani broth (LB; Liofilchem): tryptone 10 g/L, yeast extract 5 g/L, sodium chloride 5 g/L, final 
pH=7.0. 
Luria-Bertani Agar (LB-agar; Nzytech): tryptone 10 g/L, yeast extract 5 g/L, sodium chloride 10 g/L, 
agar 15 g/L, final pH=7.0. 
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 Analysis of positive clones 4.8.4
For the analysis of the lanM genes, white colonies were chosen (and also one blue 
colony, to use as a negative control) to perform colony-PCR in order to confirm the 
incorporation of the fragment into the pCR2.1 plasmid. The amplification of inserts was 
performed using the primers M13rv (5’-TCACACAGGAAACAGCTATGAC-3’) and M13fw (5’-
GTTTTCCCAGTCACGAC-3’). Each reaction was performed in a final volume of 25 μL as 
described in Table 5. However, a colony was used as DNA template. The amplification 
parameters were as follows: one step of denaturation at 95 °C for 5 min followed by 30 
cycles of denaturation at 95 °C for 30 sec, primer annealing at 52 °C for 30 sec and 
extension at 72 °C for 45 sec. A final extension step at 72 °C for 10 min was included. The 
PCR products were submitted to an electrophoresis and visualized, as described in the 
appendix 6.1. The nucleotide sequence of the amplicons with the same (or approximate) 
size as the positive control (more or less 600 bp) was determined by sequencing reaction 
(STABVIDA-Portugal). 
The nucleotide sequences obtained were compared to sequences available in the 
database using both BLASTn and BLASTx tools. 
4.9 Detection of lantibiotic mersacidin on B. amyloliquefaciens cultures’ 
supernatant 
The evaluation of mersacidin production was achieved using a mass spectrometry 
profile generated by matrix-assisted laser desorption/ionization time-of-flight (MALDI-
TOF/MS). It was known that mersacidin can be isolated from culture filtrate by extraction 
with solvents which are immiscible with water, such as butanol (Chatterjee et al., 1992). 
Thus, 0.6 volumes of 1-butanol was added to 30 mL of CFS. The CFS was obtained as 
described before in section 4.3. The mixture was shacked for 1 hour and the organic 
phase collected after centrifugation for 1 min at 10,000 rpm. Subsequently, the solvent 
was evaporated on a rotator evaporator at 50 ºC for 12 h. Finally, the extracts were 
analyzed for the mersacidin presence as described by Herzner et al. (2011). 
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6.1 Agarose gel electrophoresis 
Analysis of DNA was performed on agarose gel electrophoresis. The samples were 
mixed with 6X loading buffer in a proportion of 1:6 (v/v) and loaded in a 1% agarose gel. 
The gel was prepared with 1X of TAE buffer (Bio-Rad) and EtBr (AppliChem) to a final 
concentration of 0.5 µg/mL added before transferred the melted agarose in the running 
tray. All electrophoresis running included 0.5 µg of the DNA marker DNA Ladder Mix 
(Fermentas). Electrophoresis was generally performed at 120V for the desired time and 
the DNA was analyzed under UV light and the corresponding image was acquired in the 
ATTO image acquisition system. 
 
Loading buffer 6X: 2.5 mg/mL of bromophenol blue, 2.5 mg/mL of xylene cyanol FF and 30% (v/v) 
glycerol; stored at 4°C. 
6.2 Purification of DNA from agarose 
The purification of DNA from agarose was performed using the kit NZYGelpure 
(NZYTech), according to manufacturer’s instructions. Briefly, the desired DNA fragment 
was excised from the agarose gel with a clean scalpel and placed in a 1.5 mL 
microcentrifuge tube. The gel slice was weighted and 300 µL of Binding Buffer were 
added for each 100 mg of gel. In the cases when the gel slice weights more than 400 mg, 
two microcentrifuge tubes were used. The tube containing the gel slice was incubated at 
50 °C for 10 min and shacked occasionally until agarose was completely dissolved. The 
mixture was transferred into the NZYTech spin column placed into a Collection tube (2 
mL). Each collection tube has a maximum limit of 700 µL of sample. The samples were 
added and centrifuged at top speed (13,200 rpm) for 1 min. The flow-through was 
discarded and the column was placed back to the collection tube. This step was repeated 
until the complete addition of the sample to the NZYTech spin column. For a direct DNA 
sequencing, 500 µL of Binding Buffer were added to the column, which was centrifuged at 
top speed for 1 min. The flow-through was discarded. The DNA was washed with 600 µL 
of Binding Buffer and the centrifugation was performed as in the preceding step. The flow-
through was discharged and the column was centrifuged for an additional minute for the 
complete removal of residual ethanol. The NZYTech spin column was placed in a clean 
1.5 mL microcentrifuge tube and the DNA was eluted in 30 to 50 µL of Elution Buffer, 
concerning the subsequent application. The elution was performed after 2 min of 
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incubation at room temperature by centrifugation at top speed for 1 min. The sample was 
stored at -20 °C until further use. 
6.3 Genomic DNA extraction 
In some bacterial isolates, the extraction of genomic DNA was performed using 
DNeasy Blood & Tissue Kit (Qiagen). The bacteria were grown overnight on 5 mL of TSB 
(Merck) in a 50 mL falcon, at 26 °C, 180 rpm. For each bacterium, 2 mL of culture (1 mL 
in each 1.5 mL microcentrifuge tubes) were used for genomic DNA extraction. The cells 
were harvested for 10 min at top speed (16,100 x g) and the supernatant were discarded. 
The pellet were resuspended in 180 µL of enzymatic lysis buffer in one of the 1.5 mL 
microcentrifuge tubes and the resuspension were completely transferred to the other 1.5 
mL microcentrifuge tube and also resuspended. This mixture were incubated at 37 °C for 
30 min. After that time, 25 µL of proteinase k were added to the sample and mixed by 
vortexing. Then, 200 µL of Buffer AL were also added and mixed by vortexing. The 
samples were incubated at 70 °C for 30 minutes. Next, 200 µL of ethanol (96-100%) were 
added to the sample and mixed by vortexing. The mixture was then pipetted to the 
DNeasy Mini Spin column, which is placed in a 2 mL collection tube. The column was 
centrifuged at top speed (16,100 x g) for 1 min. The flow-through was discarded as also 
the collection tube. The DNeasy Mini Spin column was then placed on a new and clean 
collection tube and 500 µL of Buffer AW1 were added. A centrifugation of 1 min at top 
speed took place. The flow-through and the collection tube were discarded. The column 
was placed into a new 2 mL collection tube and 500 µL of Buffer AW2 were added. The 
column was centrifuged at top speed for 3 min. The flow-though was discarded, but this 
time the column was placed in the same collection tube and centrifuged at top speed 
during 1 min. This step is to ensure the membrane was dried. Once again, the flow-though 
and the collection tube were both discarded and the DNeasy Mini Spin column was placed 
in a clean 1.5 mL microcentrifuge tube and 100 µL of Buffer AE (elution buffer) were 
pipetted into the column. After this procedure, 5 µL of the genomic DNA solution were run 
in an electrophoresis gel, in order to confirm its presence on the sample. 
 
Lysis buffer preparation: 20 mM Tris-HCl pH 8; 2mM sodium EDTA; 1,2% Triton X-100. Autoclave 
this solution. This buffer is also composed by 20 mg/mL of lysozyme, which were added only before use and 
after autoclaving. 
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6.4 PCR product purification 
The purification of PCR products was performed using NZYGelpure (NZYTech) 
according to the manufacturer’s instructions. Briefly: the volume of the PCR reaction 
solution was transferred to a 1.5 mL microcentrifuge tube and distilled water was added 
until a final volume of 100 µL. Then, five volumes of binding Buffer were added and mixed 
well by vortexing. Thereafter, 100 µL of isopropanol were added and mixed well by 
vortexing. The mixture was applied to an NZYTech spin column, incubated at room 
temperature for 2 min and centrifuged at top speed (16,100 x g) for 1 min. The flow-
through was discarded and 600 µL of Wash Buffed were added to the spin column. The 
centrifugation was performed as described previously and the flow-through was 
discarded. An additional 1 min centrifugation was performed to remove the residual 
ethanol. Finally, the NZYTech spin column was placed into a clean 1.5 mL microcentrifuge 
tube and 20 µL of distilled water were added to the center of the column. The DNA-
containing column was incubated at room temperature during 2 min and then centrifuged 
for 1 min at top speed to elute the DNA. The sample was stored at -20 °C until further use. 
